

# **Washington University**

**Report on Federal Financial Assistance  
Programs in Accordance with Uniform Guidance  
For the Year Ended June 30, 2018  
Employer Identification Number: 430653611**

**Washington University**  
**Report on Federal Financial Assistance Programs in**  
**Accordance with Uniform Guidance**  
**Index**  
**June 30, 2018**

---

	<b>Page(s)</b>
<b>A. FINANCIAL STATEMENTS AND SUPPLEMENTAL INFORMATION</b>	
Report of Independent Auditors.....	1-2
Consolidated Financial Statements for the Years Ended June 30, 2018 and 2017.....	3-29
Schedule of Expenditures of Federal Awards .....	30-50
Notes to Schedule of Expenditures of Federal Awards.....	51
<b>B. REPORTS ON COMPLIANCE AND ON INTERNAL CONTROLS</b>	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i> .....	52-53
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the Uniform Guidance .....	54-55
<b>C. SCHEDULE OF INDEPENDENT AUDITORS' FINDINGS AND QUESTIONED COSTS</b>	
Part I – Summary of Auditors' Results.....	56
Part II – Financial Statement Findings .....	57
Part III – Federal Award Findings and Questioned Costs .....	57
<b>D. SUMMARY OF STATUS OF PRIOR AUDIT FINDINGS</b>	
Summary of Status of Prior Audit Findings .....	58

**Financial Statements and Supplemental Information**



## **Report of Independent Auditors**

To the Board of Trustees of Washington University:

### **Report on the Consolidated Financial Statements**

We have audited the accompanying consolidated financial statements of Washington University and its subsidiaries (the “university”), which comprise the consolidated statements of financial position as of June 30, 2018 and 2017, and the related consolidated statements of activities and changes in net assets and of cash flows for the years then ended.

### ***Management’s Responsibility for the Consolidated Financial Statements***

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### ***Auditors’ Responsibility***

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the university’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the university’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### ***Opinion***

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Washington University and its subsidiaries as of June 30, 2018 and 2017, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.



**Other Matters**

*Other Information*

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

**Other Reporting Required by Government Auditing Standards**

In accordance with *Government Auditing Standards*, we have also issued our report dated September 25, 2018 on our consideration of the university's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of the university's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the university's internal control over financial reporting and compliance.

*PricewaterhouseCoopers LLP*

St. Louis, Missouri  
September 25, 2018

**Washington University**  
**Consolidated Statements of Financial Position**  
**June 30, 2018 and 2017**

(thousands of dollars)

	<b>2018</b>	<b>2017</b>
<b>Assets</b>		
Cash and cash equivalents	\$ 366,525	\$ 128,870
Investments	9,248,311	8,522,943
Collateral received for securities lending	-	178,231
Accounts and notes receivable, net	494,685	463,682
Pledges receivable, net	439,318	202,762
Other assets	231,280	191,768
Fixed assets, net	<u>2,541,137</u>	<u>2,331,063</u>
Total assets	<u>\$ 13,321,256</u>	<u>\$ 12,019,319</u>
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$ 484,625	\$ 439,939
Liabilities under securities lending transactions	-	173,889
Deposits, advances and other	23,308	20,760
Professional liability	73,756	69,106
Deferred revenue	137,744	121,386
Liabilities under split-interest agreements	40,842	35,048
Government supported student loans	36,232	44,810
Notes and bonds payable	<u>2,030,781</u>	<u>1,632,202</u>
Total liabilities	<u>2,827,288</u>	<u>2,537,140</u>
<b>Net assets</b>		
Unrestricted	5,154,934	4,738,453
Temporarily restricted	3,413,014	2,942,867
Permanently restricted	<u>1,926,020</u>	<u>1,800,859</u>
Total net assets	<u>10,493,968</u>	<u>9,482,179</u>
Total liabilities and net assets	<u>\$ 13,321,256</u>	<u>\$ 12,019,319</u>

The accompanying notes are an integral part of these consolidated financial statements.

# Washington University

## Consolidated Statements of Activities

### Year Ended June 30, 2018

<i>(thousands of dollars)</i>	<b>Unrestricted</b>	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>June 30, 2018 Total</b>
<b>Revenues</b>				
Tuition and fees, gross	\$ 659,893	\$ -	\$ -	\$ 659,893
Less: Scholarships	(247,924)			(247,924)
Tuition and fees, net	411,969	-	-	411,969
Endowment spending distribution	315,774	7,121		322,895
Investment income	21,245	320		21,565
Gifts	80,958	326,925		407,883
Grants and contracts revenues				
Direct costs recovered	433,507			433,507
Facilities and administrative costs recovered	155,381			155,381
Patient services, net	1,327,124			1,327,124
Auxiliary enterprises - sales and services	114,870			114,870
Educational activities - sales and services	180,874			180,874
Affiliated hospital revenues	127,595			127,595
Other revenue	40,017	(540)		39,477
Net assets released from restriction	113,491	(113,491)		-
Total revenues and other support	<u>3,322,805</u>	<u>220,335</u>	<u>-</u>	<u>3,543,140</u>
<b>Expenses</b>				
Instruction	1,988,694			1,988,694
Research	537,777			537,777
Academic support	203,196			203,196
Student services	96,666			96,666
Institutional support	155,835			155,835
Auxiliary enterprises expenditures	117,153			117,153
Other deductions	33,727			33,727
Total expenses	<u>3,133,048</u>	<u>-</u>	<u>-</u>	<u>3,133,048</u>
Net operating results	<u>189,757</u>	<u>220,335</u>	<u>-</u>	<u>410,092</u>
<b>Non-operating revenues and (expenses)</b>				
Investment returns net of endowment spending	225,639	260,272	(594)	485,317
Permanently restricted gifts			119,904	119,904
Gain (loss) on fixed asset disposals and other	1,085	(10,460)	5,851	(3,524)
Fair value of assets acquired in excess of consideration paid				-
Non-operating, net	<u>226,724</u>	<u>249,812</u>	<u>125,161</u>	<u>601,697</u>
Change in net assets	416,481	470,147	125,161	1,011,789
<b>Net assets</b>				
Beginning of the year	<u>4,738,453</u>	<u>2,942,867</u>	<u>1,800,859</u>	<u>9,482,179</u>
End of the year	<u>\$ 5,154,934</u>	<u>\$ 3,413,014</u>	<u>\$ 1,926,020</u>	<u>\$ 10,493,968</u>

The accompanying notes are an integral part of these consolidated financial statements.

**Washington University**  
**Consolidated Statements of Activities**  
**Year Ended June 30, 2017**

<i>(thousands of dollars)</i>	<b>Unrestricted</b>	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>June 30, 2017 Total</b>
<b>Revenues</b>				
Tuition and fees, gross	\$ 626,033	\$ -	\$ -	\$ 626,033
Less: Scholarships	(232,546)			(232,546)
Tuition and fees, net	393,487	-	-	393,487
Endowment spending distribution	298,994	6,596		305,590
Investment income	12,174	369		12,543
Gifts	75,839	107,461		183,300
Grants and contracts revenues				
Direct costs recovered	408,630			408,630
Facilities and administrative costs recovered	144,988			144,988
Patient services, net	1,194,694			1,194,694
Auxiliary enterprises - sales and services	115,768			115,768
Educational activities - sales and services	156,775			156,775
Affiliated hospital revenues	116,731			116,731
Other revenue	35,849			35,849
Net assets released from restriction	127,438	(127,438)		-
Total revenues and other support	3,081,367	(13,012)	-	3,068,355
<b>Expenses</b>				
Instruction	1,812,306			1,812,306
Research	507,786			507,786
Academic support	185,692			185,692
Student services	88,918			88,918
Institutional support	146,386			146,386
Auxiliary enterprises expenditures	115,088			115,088
Other deductions	37,237			37,237
Total expenses	2,893,413	-	-	2,893,413
Net operating results	187,954	(13,012)	-	174,942
<b>Non-operating revenues and (expenses)</b>				
Investment returns net of endowment spending	232,055	256,987	3,691	492,733
Permanently restricted gifts			68,466	68,466
Gain (loss) on fixed asset disposals and other	(42,563)	(3,983)	10,219	(36,327)
Fair value of assets acquired in excess of consideration paid	23,761	3,573	10,250	37,584
Non-operating, net	213,253	256,577	92,626	562,456
Change in net assets	401,207	243,565	92,626	737,398
<b>Net assets</b>				
Beginning of the year	4,337,246	2,699,302	1,708,233	8,744,781
End of the year	\$ 4,738,453	\$ 2,942,867	\$ 1,800,859	\$ 9,482,179

The accompanying notes are an integral part of these consolidated financial statements.



# Washington University

## Consolidated Statements of Cash Flows

### Years Ended June 30, 2018 and 2017

(thousands of dollars)

	<b>2018</b>	<b>2017</b>
<b>Cash flows from operating activities</b>		
Change in net assets	\$ 1,011,789	\$ 737,398
Adjustments to reconcile change in net assets to cash provided by operating activities		
Realized and unrealized net gains on investments	(835,751)	(804,486)
Depreciation expense	180,470	173,987
Permanently restricted gifts	(119,904)	(68,466)
Investments received as gifts - not permanently restricted	(11,765)	(8,797)
Proceeds from sales of investments received as gifts	11,765	8,797
Debt extinguishment costs	-	27,738
Fair value of non-cash assets acquired in excess of consideration paid	-	(37,509)
Other non-cash adjustments	(10,083)	7,955
Changes in assets and liabilities		
Accounts and notes receivable, net	(28,290)	(19,760)
Pledges receivable, net	(215,761)	26,738
Accounts payable and accrued expenses	33,066	55,272
Deposits and advances	(17,077)	(25,256)
Other assets and liabilities	14,301	(7,204)
Net cash provided by operating activities	<u>12,761</u>	<u>66,407</u>
<b>Cash flows from investing activities</b>		
Proceeds from sales and maturities of investments	10,389,420	6,471,569
Purchases of investments	(10,278,075)	(6,414,436)
Sales (Purchases) of investments with securities lending collateral	173,889	(130,431)
Purchases of fixed assets	(379,906)	(223,272)
Student loans disbursed	(18,161)	(19,558)
Student loan payments received	23,087	22,655
Other	55	(28)
Net cash used in investing activities	<u>(89,691)</u>	<u>(293,501)</u>
<b>Cash flows from financing activities</b>		
Principal payments of debt	(22,788)	(272,093)
Proceeds from long-term debt issuance	423,296	288,663
Contributions restricted for long-term investment	52,038	16,601
Proceeds from sales of investments received as gifts	46,553	48,970
Securities lending collateral (sold) received, net	(173,889)	130,431
Debt extinguishment costs	-	(27,738)
Other	(10,625)	(2,313)
Net cash provided by financing activities	<u>314,585</u>	<u>182,521</u>
Net increase/(decrease) in cash	237,655	(44,573)
<b>Cash</b>		
Beginning of year	<u>128,870</u>	<u>173,443</u>
End of year	<u>\$ 366,525</u>	<u>\$ 128,870</u>
<b>Supplemental data</b>		
Interest paid in cash	\$ 57,122	\$ 49,522
<b>Noncash activities</b>		
Fair value of assets acquired in excess of consideration paid	-	(37,509)
Contributions of securities and other noncash assets	59,157	58,242
Net change in accounts payable for fixed assets	4,328	(6,568)
Net change in accounts receivable for investments	(6,654)	(678)
Net change in accounts payable for investments	7,090	2,483

The accompanying notes are an integral part of these consolidated financial statements.

# Washington University

## Notes to the Consolidated Financial Statements

### Years Ended June 30, 2018 and 2017

---

*(All amounts in thousands of dollars)*

#### 1. Summary of Significant Accounting Policies

##### **Organization**

Washington University in St. Louis (the “university”), is an institution of higher education that, in furtherance of its role as a charitable and educational institution, engages in various activities, including instruction, research and provision of medical care.

##### **Basis of Presentation and Use of Estimates**

The consolidated financial statements have been prepared on the accrual basis of accounting. The consolidated financial statements are consolidated to include the accounts of the university and its affiliates.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, the estimated useful lives of buildings and equipment, the fair value of certain investments (see footnote 2), the degree of precision in calculation of self-insurance reserves and adequacy of allowances for doubtful accounts. Actual results could differ from those estimates.

##### **Net Assets**

Resources are classified for accounting and reporting purposes according to externally (donor) imposed restrictions. Descriptions of the net asset categories follow:

- Unrestricted net assets are free of donor-imposed restrictions.
- Temporarily restricted net assets consist of gifts and related earnings that are subject to donor-imposed restrictions or legal stipulations that have not yet been met by actions of the university and/or passage of time.
- Permanently restricted net asset balances include gifts and trusts which, by donor restriction, are required to be held in perpetuity.

Revenues from sources other than contributions and investment returns are reported as increases in unrestricted net assets. Contributions are reported as increases in the appropriate category of net assets, except that contributions which impose restrictions that are met in the same fiscal year they are received are included in unrestricted revenues. Gains and investment income that are limited to specific uses by donor-imposed restrictions are reported as increases in unrestricted net assets if the restrictions are met in the same reporting period as the gains and income are recognized, except for gains and investment income earned by investment of donor-restricted endowments. Such amounts are not reported as unrestricted net assets until appropriated for expenditure. When a donor restriction expires, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the Consolidated Statements of Activities as net assets released from restrictions. Permanently restricted gifts received are reported in the non-operating section of the Consolidated Statements of Activities. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the university reports

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

---

*(All amounts in thousands of dollars)*

expirations of donor restrictions when the donated or acquired long-lived assets are placed in service. Expenses are reported as decreases in unrestricted net assets.

Temporarily and permanently restricted net assets are for the following purposes.

	<b>2018</b>		<b>2017</b>	
	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>
General activities	\$ 2,355,920	\$ 1,300,627	\$ 1,996,993	\$ 1,226,591
Student assistance	553,676	448,502	472,681	399,311
Buildings and renovations	491,345	151,312	460,451	150,658
Life income	12,073	25,579	12,742	24,299
Total	\$ 3,413,014	\$ 1,926,020	\$ 2,942,867	\$ 1,800,859

**Investments**

Investment gains (losses) in excess of endowment spending distribution and the unrealized appreciation (depreciation) on investments are reported in the non-operating section of the Consolidated Statements of Activities. Investments acquired by gift or bequest are initially recorded at market or appraised value at the date so acquired.

At June 30, 2018, investments include \$133,430 purchased with unexpended proceeds from the Series 2017 A Missouri Health and Educational Facilities Authority (MOHEFA) revenue bonds issued July 6, 2017. At June 30, 2017, investments included \$7,582 purchased with unexpended proceeds from the Series 2016 A and Series 2014 A MOHEFA revenue bonds issued in February 2016 and August 2014, respectively. These funds may only be expended for specific construction project costs and costs of issuance related to the MOHEFA bonds.

**Fair Value of Financial Instruments**

The carrying amount of accrued investment income, accounts receivable, accounts payable and other various accruals approximate fair value because of the short maturity of these financial instruments. The carrying amount of notes and bonds payable with variable interest rates approximates their fair value because the variable rates reflect current market rates for bonds with similar maturities and credit quality.

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

---

*(All amounts in thousands of dollars)*

**Fixed Assets**

Fixed assets are stated at cost or at fair market values if received as a gift, less accumulated depreciation, computed on a straight-line basis over the estimated useful lives of the assets. Fixed assets include equipment and other assets acquired through sponsored programs during which title is retained by the resource provider. It is probable the university will be permitted to keep the assets when the program terminates. The cost and accumulated depreciation of fixed assets are removed from the records at the time of disposal. Gains and losses on fixed asset disposals are reported in the non-operating section of the Consolidated Statements of Activities. Fixed assets by classification at June 30, 2018 and 2017 consist of the following:

	<u>2018</u>	<u>2017</u>
Construction in progress	\$ 400,842	\$ 282,513
Land and improvements to land	150,995	146,326
Buildings	3,850,398	3,673,747
Equipment	<u>553,156</u>	<u>486,528</u>
Total cost	4,955,391	4,589,114
Accumulated depreciation	<u>(2,414,254)</u>	<u>(2,258,051)</u>
Total, net	<u>\$ 2,541,137</u>	<u>\$ 2,331,063</u>

**Collections**

In addition to the Mildred Lane Kemper Art Museum, the university archives rare book collections, works of art, literary works, historical treasures and artifacts. These collections are protected and preserved for public exhibition, education, research and the furtherance of public service. They are neither disposed of for financial gain nor encumbered in any manner. Accordingly, such collections are not recognized or capitalized for financial statement purposes.

**Financing Receivables**

Financing receivables are principally loans made to students or their parents utilizing gifts, endowment payout, and university resources designated for that purpose and from funds provided by the United States government under the Federal Perkins and Health Professional Student Loan programs. Loan funds are reported at estimated realizable value, as it is not practical to determine the fair value of loan fund receivables, which include a large component of federally sponsored student loans. Federally sponsored student loans have significant government restrictions as to marketability, interest rates, and repayment terms. Federal funds are ultimately refundable to the government and are recognized as a liability in the Consolidated Statements of Financial Position (see footnote 5).

The university's loan portfolio includes over 8,800 individual loans and is geographically diverse. Loans that are made are due on the first day of the month and are considered past due if the minimum payment is not received within thirty-one days past the due date. At June 30, 2018 and 2017, respectively, 92% and 92% of the parent loans and 77% and 80% of the institutional student loans were considered current. Income earned on financing receivables is recorded on an accrual basis.

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

---

*(All amounts in thousands of dollars)*

**Deferred Revenue**

Deferred revenue is recognized on an accrual basis when payments for services are received in advance of performance by the university. The principle components of deferred revenue are clinical trial receipts, Grants and Contracts, and prepaid tuition and housing.

**Tuition and Financial Aid**

Demonstrated financial need is the major criteria for undergraduate students to receive financial aid. Graduate students often receive tuition support in connection with research assistant, teaching assistant and fellowship appointments. Total financial aid granted to students by the university, including aid provided to employees and their dependents, was \$356,526 in 2018 and \$326,646 in 2017. The table below identifies student aid by type. Scholarships are reported net against tuition in the Consolidated Statements of Activities. Other amounts are reported as expenses.

	<u>2018</u>	<u>2017</u>
Scholarships from unrestricted sources	\$ 188,072	\$ 182,362
Scholarship support from gifts, endowment and other restricted sources	<u>59,853</u>	<u>50,184</u>
Total scholarships	247,925	232,546
Employee and dependent tuition benefits	35,025	32,628
Stipends	71,535	58,919
Work study	<u>2,041</u>	<u>2,553</u>
Total	<u>\$ 356,526</u>	<u>\$ 326,646</u>

**Gifts**

Gifts, including unconditional promises to give, are recognized as revenues in the period the gift or promise is received. Gifts received for permanent endowments or perpetual trusts are reported as non-operating revenues. Gifts of assets other than cash are recorded at their estimated fair value at the date of gift and, unless instructed otherwise by the donor, are liquidated upon receipt or as soon as practical thereafter.

Conditional gifts and promises to give are not recognized until the conditions on which they depend are substantially met. Gifts, in the form of unconditional promises to give, to be received after one year are discounted at credit-adjusted tax exempt borrowing rates in accordance with fair value accounting. Pledges outstanding are discounted with rates ranging from 0.78% to 2.04%. Amortization of the discount is recorded as gift revenue. The university has received gifts which are recorded as gift revenue in the period the gift was made but are payable over a specified payment schedule of up to 10 years or more. During the gift payment term, the university is exposed to credit risk for the entity or individual that has made the gift. An allowance is made for uncollectible unconditional promises to give based upon management's judgment, past collections experience and other relevant factors. During 2018, the university received a pledge of \$20,000 annually to be received over a period of 10 years.

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

---

*(All amounts in thousands of dollars)*

A summary of pledges receivable is as follows:

	<b>2018</b>	<b>2017</b>
In one year or less	\$ 148,143	\$ 101,098
Between two and five years	208,318	99,520
Over five years	108,721	10,543
	<u>465,182</u>	<u>211,161</u>
Less:		
Discount	(19,739)	(2,792)
Allowance for uncollectible amounts	(6,125)	(5,607)
Total	<u>\$ 439,318</u>	<u>\$ 202,762</u>

**Patient Services Revenue**

The university recognizes revenues in the period in which services are rendered. The university has agreements with third-party payers that provide for payment to the university at amounts that are generally less than its established rates. Accordingly, patient revenue is reported net of contractual allowances, at estimated net realizable amounts from patients, third-party payers and others for services rendered. Also, reported in this caption are cost reimbursements from hospitals for services provided by university personnel in support of the hospital's clinical activities.

**Tuition and Fee Revenue**

Tuition and fee revenue, net of scholarships, is recorded in the fiscal year in which the educational programs are conducted.

**Auxiliary Enterprises – Sales and Services**

Auxiliary enterprises sales and services revenue is recorded in the fiscal year in which earned. This revenue is composed primarily of on and off campus housing charges, dining services, and parking and transportation fees.

**Educational Activities – Sales and Services**

Educational activities sales and services revenue is recorded in the fiscal year in which it is earned. This revenue is composed of a number of activities including clinical trial revenues, management services and salary reimbursements from affiliated hospitals, consulting, laboratory fees, conference center revenues and revenues from licensing and royalties.

**Affiliated Hospital Revenues**

Affiliated hospital revenue is recorded in the fiscal year in which earned. This revenue is composed of amounts received from affiliated hospitals for various services as more fully described in footnote 10.

# Washington University

## Notes to the Consolidated Financial Statements

### June 30, 2018 and 2017

---

*(All amounts in thousands of dollars)*

#### **Grants and Contracts**

The university receives grant and contract revenue from governmental and private sources. Revenue associated with the direct costs of sponsored programs is generally recognized as the related costs are incurred. The university records revenue in unrestricted net assets upon its recovery of direct and indirect costs applicable to those sponsored programs that provide for the full or partial reimbursement of such costs. The recovery of indirect costs, also referred to as facilities and administrative costs is based on negotiated rates and represents recoveries of facilities and administrative costs incurred under grants and contracts agreements. Recovery of facilities and administrative costs of Federally sponsored programs is at rates negotiated with the Department of Health and Human Services. During fiscal 2018, the university and the Federal government operated under an agreement that established facilities and administrative cost reimbursement rates under Federal grants and contracts through June 30, 2021.

#### **Operating Results and Allocation of Certain Expenses**

The university's measure of operations as presented in the Consolidated Statements of Activities includes income from tuition and fees, grants and contracts, medical services, contributions for operating programs, the endowment spending distribution and other revenues. Operating expenses are reported on the Consolidated Statements of Activities by functional categories, after allocating costs for operation and maintenance of plant, interest on indebtedness and depreciation expense. Operation and maintenance of plant and depreciation are allocated to functional categories largely based on square footage. Interest expense is allocated based on specific identification of the uses of debt proceeds. Instruction expenses include instruction, departmental research and patient care costs. Operating results exclude investment gains (losses) except for the portion of gains utilized for the endowment spending distribution, permanently restricted gifts, the fair value of net assets acquired in excess of consideration paid, and other non-operating amounts.

#### **Split-Interest Agreements**

The university's split-interest agreements with donors consist primarily of charitable gift annuities and irrevocable charitable remainder trusts for which the university serves as trustee. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements. Contribution revenues for charitable gift annuities and charitable remainder trusts are recognized after recording liabilities for the present value of the estimated future payments to be made to the respective donors and/or other beneficiaries. The discount rate used is a credit-adjusted rate in existence at the date of the gift. The rates used range from 1.72% to 3.03% for 2018 and 1.02% to 3.03% for 2017. Annually, the university records the change in value of split-interest agreements by recording at fair value the assets that are associated with each trust and recalculating the liability for the present value of the estimated future payments to be made to the donors and/or other beneficiaries.

#### **Cash and Cash Equivalents**

The university considers cash on hand and in banks and all highly liquid financial instruments with an original maturity of 90 days or less, except those amounts assigned to and invested by its investment managers, which amounts are classified as investments, to be cash and cash equivalents.

# Washington University

## Notes to the Consolidated Financial Statements

### June 30, 2018 and 2017

---

*(All amounts in thousands of dollars)*

#### **Income Taxes**

The university is exempt from federal income taxes under Section 501 (c)(3) of the Internal Revenue Code except to the extent the university has unrelated business income or consolidated for-profit affiliates incur taxes. The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. The Act impacts the university in several ways, including new excise taxes on executive compensation and net investment income, increases to unrelated business taxable income (UBTI) by the amount of certain fringe benefits for which a deduction is not allowed, changes to the net operating loss rules, repeal of the alternative minimum tax (AMT), and the computation of UBTI separately for each unrelated trade or business. Further, the Act reduces the U.S. federal corporate tax rate and federal corporate unrelated business income tax rate from 35% to 21%. The overall impact of the Act remains uncertain and the full impact of the Act will not be known until further regulatory guidance is provided to assist the university with calculating income and excise tax liabilities. The university continues to evaluate the impact of tax reform on the organization.

As of June 30, 2018, the university has made a reasonable estimate of the determinable effects of the enactment of the Act on existing deferred tax balances. These amounts are provisional, subject to change and not material to the university’s consolidated financial statements. Management believes the university has no uncertain tax positions that result in material unrecognized tax expense/benefits.

#### **Fair Value of Net Assets Acquired in Excess of Consideration Paid**

The Barnard Free Skin and Cancer Hospital, also known as Barnard Cancer Institute (BCI), was established in accordance with the will of George D. Barnard principally to provide care, treatment and hospitalization to persons suffering from cancer or skin diseases and diseases allied thereto. In connection with termination of a trust supporting BCI and a court-approved settlement agreement entered into in 2006, the exempt purposes of BCI were redefined to consist of (a) providing financial support for medical, surgical and/or nursing care to persons suffering from cancer or skin diseases or diseases allied thereto who are unable to pay for such care, (b) the study of cancer, and (c) outreach programs and the dissemination of information in regard to these diseases and their treatment. BCI leases its owned property to the university or Barnes Jewish Hospital. BCI has no employees and contracts with the university for administrative services. University personnel occupy a majority of seats on the board of directors of BCI. Effective July 1, 2016, BCI entered into a contract with the university to pool its endowment with the endowment of the university for investment purposes, with the result that the BCI endowment is managed according to the university’s endowment policy. Based on the factors of majority board control and combined economic interest, the assets, liabilities and operating results of BCI have been consolidated with the university financial results as of and for the fiscal year ended June 30, 2017. The net assets of BCI as of July 1, 2016 are reported as Fair value of net assets acquired in excess of consideration paid on the Consolidated Statements of Activities. BCI assets, liabilities and net assets at June 30, 2017 were \$38,739, \$187, and \$38,552, respectively. BCI revenues and changes in net assets for 2018 and 2017 were not material to the university’s financial statements.



# Washington University

## Notes to the Consolidated Financial Statements

### June 30, 2018 and 2017

---

*(All amounts in thousands of dollars)*

#### **Recent Accounting Pronouncements**

During fiscal 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-14, Presentation of Financial Statements of Not-for-Profit Entities. ASU 2016-14, which will be effective for the university in fiscal 2019, will provide for presentation in the financial statements of two net asset categories; net assets with donor restrictions and net assets without donor restrictions, instead of the currently required three categories. Among other changes are greater disclosure of self-imposed limits on the use of resources without donor restrictions; qualitative and quantitative information on financial resources and liquidity; and expenses reported in both natural and functional classifications. The university is evaluating the impact of ASU 2016-14 to the consolidated financial statements.

During fiscal 2016, the FASB issued ASU 2016-02, Leases. The ASU requires lessees to recognize in the Statements of Financial Position for leases with a term of greater than one year, a liability to make lease payments and a right-of-use asset representing its right to use the asset for the lease term. Generally, lease payments will be recognized as interest expense and as a reduction of the liability. The asset will be amortized over the life of the lease. Accounting by a lessor will be largely unchanged from that required by current generally accepted accounting principles. Adoption of ASU 2016-02 is required for the university's fiscal year 2020. The university is evaluating the impact to the consolidated financial statements.

During 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09, effective in fiscal 2019, affects all contracts entered into with customers that result in a transfer of goods or services or a transfer of nonfinancial assets. The core principle of the standard is for organizations to recognize revenue in a way that depicts the transfer of goods or services to customers in amounts that reflect the consideration (payment) to which the organization expects to be entitled. Since 2014 the FASB has issued a number of clarifying updates. The university is currently evaluating the impact the adoption of ASU 2014-09 and subsequent updates will have on its consolidated financial statements.

## **2. Fair Value**

The university follows FASB guidance for fair value measurements. This guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The FASB guidance establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the university and unobservable inputs reflect the university's assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

# Washington University

## Notes to the Consolidated Financial Statements

### June 30, 2018 and 2017

(All amounts in thousands of dollars)

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the university for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

- Level 1 Quoted prices in active markets for identical assets or liabilities, such as exchange traded equity securities.
- Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the same term of the assets or liabilities. Examples of Level 2 include U.S. Treasury securities and corporate bonds.
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table presents the financial instruments carried at fair value as of June 30, 2018, on the Consolidated Statements of Financial Position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$564,851.

	<b>Quoted Prices in Active Markets (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2)</b>	<b>Significant Unobservable Inputs (Level 3)</b>	<b>Measured at Net Asset Value</b>	<b>Balance June 30, 2018</b>
<b>Investments</b>					
Public equity					
Domestic	\$ 65,034	\$ 27	\$ -	\$ 1,457,753	\$ 1,522,814
International	189,839	-	-	1,358,790	1,548,629
Fixed income - Nominal	-	630,837	-	-	630,837
Absolute return	-	-	-	1,682,094	1,682,094
Private equities	-	-	118,087	2,349,105	2,467,192
Short-term investments	353,806	5,286	-	-	359,092
Real assets	-	-	18,833	703,925	722,758
Other investments	177,681	(1,537)	67,688	33,190	277,022
Total investments at fair value	786,360	634,613	204,608	7,584,857	9,210,438
Fixed income assets received from security borrowers	-	-	-	-	-
Total assets reported at fair value	<u>\$ 786,360</u>	<u>\$ 634,613</u>	<u>\$ 204,608</u>	<u>\$ 7,584,857</u>	<u>\$ 9,210,438</u>

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

(All amounts in thousands of dollars)

The following table presents the financial instruments carried at fair value as of June 30, 2017, by caption on the Consolidated Statements of Financial Position and by the valuation hierarchy defined above. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$672,807.

	<b>Quoted Prices in Active Markets (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2)</b>	<b>Significant Unobservable Inputs (Level 3)</b>	<b>Measured at Net Asset Value</b>	<b>Balance June 30, 2017</b>
<b>Investments</b>					
Public equity					
Domestic	\$ 159,856	\$ 7,163	\$ -	\$ 1,489,956	\$ 1,656,975
International	397,290	-	-	1,441,174	1,838,464
Fixed income - Nominal	-	751,331	-	-	751,331
Absolute return	-	-	-	1,738,040	1,738,040
Private equities	-	-	94,045	1,476,963	1,571,008
Short-term investments	181,168	1,534	-	-	182,702
Real assets	-	-	-	595,750	595,750
Other investments	45,427	(2,057)	66,645	33,636	143,651
Total investments at fair value	783,741	757,971	160,690	6,775,519	8,477,921
Fixed income assets received from security borrowers	-	178,231	-	-	178,231
Total assets reported at fair value	\$ 783,741	\$ 936,202	\$ 160,690	\$ 6,775,519	\$ 8,656,152

Included as investments on the Consolidated Statements of Financial Position, at June 30, 2018 and 2017, respectively, but not reported in the tables above, are accrued investment income of \$4,114 and \$4,484 and investments in affiliates of \$33,759 and \$40,538, which are recorded on the equity basis of accounting. Beneficial interests in perpetual trusts held by third parties are valued at the present value of the future distributions expected to be received over the term of the agreement.

Following is a description of the university's valuation methodologies for assets and liabilities measured at fair value. The methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the university believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Fair value for Level 1 is based upon quoted prices in active markets that the university has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets. The university does not adjust the quoted price for such assets and liabilities.

Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources including market participants, dealers, and brokers.

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

---

*(All amounts in thousands of dollars)*

Fair value for Level 3 is based on valuation techniques that use significant inputs that are unobservable as they trade infrequently or not at all.

Investments measured at net asset value primarily consist of the university's ownership in alternative investments (principally limited partnership interests in absolute return, private equity investments, real assets, and other similar funds). The fair values (Net Asset Value ("NAV") or partner's capital per share) of the securities held by limited partnerships that do not have readily determinable fair values are determined by the respective general partners and are based on appraisals or other estimates that require varying degrees of judgment. If no public market exists for the investments, the fair value is determined by the general partners taking into consideration significant unobservable inputs including, among other things, the cost of the investments, prices of recent significant placements of investments of the same issuer, and subsequent developments concerning the companies to which the investments relate. Excluding the cost of the investment, significant increases or decreases in the remainder of those inputs could result in a significantly higher or lower fair value measurement. The university has performed due diligence with respect to these investments to ensure NAV or partner's capital per share is an appropriate measure of fair value as of June 30. NAVs are calculated by the investees in a manner consistent with generally accepted accounting principles for investment companies.

Significant terms of agreements with external investment managers or funds by major classes of investments are provided in the following tables.

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2018:

<b>Investments</b>	<b>Unfunded Commitment (1)</b>	<b>Remaining Life (2)</b>	<b>Redemption Terms</b>	<b>Redemption Restrictions</b>
Public equities	\$ 180,000	4 Years - No Limit	Daily to annually, with 1 day-1 year notice	Lock-up provision periods range from 0 to 5 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments	-	No Limit	Daily, 1-2 days notice	No lock-up provision periods
Absolute return	95,230	No Limit	Monthly to annually, with 30 -180 days notice	Lock-up provision periods range from 0 to 3 years. Certain investments include side pockets subject to external manager discretion.
Private equities	1,541,661	0 - 23 Years	Not eligible for redemption	Not redeemable
Real assets	419,530	0 - 12 Years	Not eligible for redemption	Not redeemable
Total	\$ 2,236,421			

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

---

*(All amounts in thousands of dollars)*

Footnote (1): The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): Assuming all extension options under the agreements are exercised and approved

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2017:

<b>Investments</b>	<b>Unfunded Commitment</b>	<b>Remaining Life (1)</b>	<b>Redemption Terms</b>	<b>Redemption Restrictions</b>
Public equities	\$ 18,750	No Limit	Daily to Annually, 1- 180 days notice	Lock-up provision periods range from 0 to 3 years. Some investments contain side pockets subject to external manager discretion.
Fixed income and short-term investments	-	No Limit	Daily, 1-2 days notice	No lock-up provision periods
Absolute return	135,385	No Limit	Monthly to Annually, 3 days to 90 days notice	Lock-up provision periods range from 0 to 2 years. Some investments contain side pockets subject to external manager discretion.
Private equities	1,570,532	0 - 24 Years	Not eligible for redemption	Not redeemable
Real assets	332,243	0 - 13 Years	Not eligible for redemption	Not redeemable
Total	<u>\$ 2,056,910</u>			

Footnote (1): Assuming all extension options under the agreements are exercised and approved

**Public Equities**

Public equities include investments in publicly –traded securities in domestic, developed international, emerging, and frontier markets. The majority of assets are held in pooled comingled funds which are valued at NAV as described above. Investments held in custody accounts are valued at quoted market price in accordance with Level 1 and Level 2 valuation techniques as described above.

# Washington University

## Notes to the Consolidated Financial Statements

### June 30, 2018 and 2017

---

(All amounts in thousands of dollars)

#### Fixed Income and Short-Term Investments

Investments in this class include domestic and international nominal fixed income instruments. Fixed income investments are held principally as liquid vehicles for operating needs and as a source of diversification. A significant component of non-endowment fixed income investments is held in highly liquid funds. The valuation of these funds is determined using a market approach in accordance with the techniques for Level 2 as described above.

#### Absolute Return

Investments in absolute return are typically held in commingled funds that employ various uncorrelated investment strategies including but not limited to long/short equity, event driven and relative value. These funds are valued at net asset value as described above.

#### Private Equities

Investments in private equities strategies are made in targeted categories including buyout, venture capital, distressed credit, and corporate finance. Redemptions of such funds are not permitted and distributions are received as underlying investments are liquidated. These funds are primarily valued at net asset value as described above.

#### Real Assets

Investments in the real assets class are made in targeted categories. The majority of these assets are held in nonredeemable fund structures that invest primarily in real estate and natural resources. These funds are primarily valued at net asset value as described above.

The following tables roll forward the Statements of Financial Position amounts for financial instruments classified by the university within Level 3 of the fair value hierarchy defined above for the years ended June 30, 2018 and 2017.

	<b>Balance June 30, 2017</b>	<b>Net Realized and Unrealized Gains (Losses)</b>	<b>Purchases, Sales and Settlements Net</b>	<b>Transfers in/(out) of Level 3, net</b>	<b>Balance June 30, 2018</b>
Investments (by strategy)					
Private equities	\$ 94,045	\$ 4,933	\$ 16,109	\$ 3,000	\$ 118,087
Real assets	-	(214)	9,945	9,102	18,833
Other investments	66,645	2,890	6,719	(8,566)	67,688
Total	<u>\$ 160,690</u>	<u>\$ 7,609</u>	<u>\$ 32,773</u>	<u>\$ 3,536</u>	<u>\$ 204,608</u>

The amount of realized and unrealized gains (losses) for Level 3 investments for the period included in net assets attributable to the change in unrealized gains or losses relating to assets still held at June 30, 2018, reported as investment returns net of endowment spending in the Statements of Activities by type of investment is:

Private equities	\$ 4,968
Real assets	(27,190)
Other investments	<u>1,339</u>
Total	<u>\$ (20,883)</u>

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

(All amounts in thousands of dollars)

	<b>Balance June 30, 2016</b>	<b>Net Realized and Unrealized Gains (Losses)</b>	<b>Purchases, Sales and Settlements Net</b>	<b>Transfers in/(out) of Level 3, net</b>	<b>Balance June 30, 2017</b>
Investments (by strategy)					
Private equities	\$ 141,248	\$ 6,923	\$ (54,126)	\$ -	\$ 94,045
Other investments	62,683	3,307	1,822	(1,167)	66,645
Total	<u>\$ 203,931</u>	<u>\$ 10,230</u>	<u>\$ (52,304)</u>	<u>\$ (1,167)</u>	<u>\$ 160,690</u>

The amount of realized and unrealized gains (losses) for Level 3 investments for the period included in net assets attributable to the change in unrealized gains or losses relating to assets still held at June 30, 2017, reported as investment returns net of endowment spending in the Statements of Activities by type of investment is:

Private equities	\$ 7,217
Other investments	2,180
Total	<u>\$ 9,397</u>

**3. Investment Return**

The following summarizes the return on investments. Investment income represents earnings on non-endowed funds. Return on investments is presented net of investment management fees. Certain investments, including some but not all of those in the absolute return and private equity categories, report investment returns net of fees. Other fees paid directly to investment managers and internal investment management costs were \$69,011 and \$64,499 for 2018 and 2017, respectively.

	<b>2018</b>	<b>2017</b>
Investment income	\$ 21,565	\$ 12,543
Pooled endowment dividends and interest income, net of investment management fees	(27,538)	(6,164)
Pooled endowment distribution in excess of income	350,433	311,754
Pooled endowment spending distribution	322,895	305,590
Investment gains, net	835,751	804,487
Gains distributed as endowment distribution	(350,433)	(311,754)
Investment gains net of endowment spending distribution	485,318	492,733
Net investment return	<u>\$ 829,778</u>	<u>\$ 810,866</u>

At June 30, 2018, the university had no securities out on loan. During the current fiscal year, the university terminated all accounts which had lendable securities. At June 30, 2017, investments with a fair value of \$173,570 were loaned to various brokers on an open-ended basis for average periods varying from several days to several months, depending on the type of loan. The university receives lending fees and continues to earn interest and dividends on the loaned securities. These securities are returnable on demand and are collateralized by cash deposits or U.S. Treasury securities amounting to 102.7% of the market value of the securities loaned at June 2017.

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

---

*(All amounts in thousands of dollars)*

The university is indemnified against borrower default by the financial institution that is acting as its lending agent. The borrowers provided \$178,207 of collateral in the form of cash or U.S. Treasury securities for the loaned securities at June 30, 2017. Cash collateral is reinvested in other vehicles by the lending agent. Cash and noncash collateral had a fair value of \$178,231 at June 30, 2017 and is reported in Collateral received for securities lending on the Consolidated Statements of Financial Position. The cost basis of collateral of \$173,889 at June 30, 2017 is reported as Liabilities under securities lending transactions on the Consolidated Statements of Financial Position.

**4. Endowment**

The state of Missouri has adopted legislation that incorporates the provisions outlined in the Uniform Prudent Management of Institutional Funds Act (UPMIFA). The statutory guidelines contained in this legislation relate to the prudent management, investment, and expenditure of donor-restricted endowment funds held by charitable organizations. Additionally, the legislation specifies factors for fiduciaries to consider prior to making a decision to appropriate from or accumulate into an institution's endowment funds.

At June 30, 2018, the university's endowment consists of 3,541 individual donor-restricted endowment funds and Board of Trustees or management-designated endowment funds for a variety of purposes plus split-interest agreements and other net assets where the assets have been designated for endowment. The net assets associated with endowment funds, including funds designated by the Board of Trustees or management to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The university has interpreted Missouri UPMIFA as requiring the preservation of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the university classifies as permanently restricted net assets, (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted until the donor-imposed stipulations attached to those amounts have been met by actions of the university and/or passage of time and appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA.

Endowment net asset composition, which includes the effect of changes in endowment investments as well as other endowment-related assets and liabilities, by type of fund as of June 30, 2018:

	<b>Unrestricted</b>	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>Total</b>
Donor-restricted endowment funds	\$ (166)	\$ 2,816,366	\$ 1,833,276	\$ 4,649,476
Board-designated endowment funds	2,757,498	233,195	-	2,990,693
Total endowment funds	<u>\$ 2,757,332</u>	<u>\$ 3,049,561</u>	<u>\$ 1,833,276</u>	<u>\$ 7,640,169</u>



**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

(All amounts in thousands of dollars)

Changes in endowment net assets for the year ended June 30, 2018:

	<b>Unrestricted</b>	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>Total</b>
<b>Endowment net assets, beginning of year</b>	\$ 2,561,367	\$ 2,795,236	\$ 1,729,427	\$ 7,086,030
Investment return				
Net investment income	(11,918)	(14,423)		(26,341)
Net appreciation (realized and unrealized)	367,415	479,354	(565)	846,204
Total investment return	355,497	464,931	(565)	819,863
Gifts	140	559	106,557	107,256
Appropriation of endowment assets for expenditure	(139,749)	(183,146)	-	(322,895)
Net transfers of funds	29,825	(6,866)	5,362	28,321
Allocation of endowment return to treasurers investment pool	(53,623)	(20,933)	-	(74,556)
Reclassification of deficits in donor-designated funds	35	(35)	-	-
Other activity	3,840	(185)	(7,505)	(3,850)
<b>Endowment net assets, end of year</b>	<b>\$ 2,757,332</b>	<b>\$ 3,049,561</b>	<b>\$ 1,833,276</b>	<b>\$ 7,640,169</b>

Of the amount classified as temporarily restricted endowment net assets, \$2,465,832 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Endowment net asset composition by type of fund as of June 30, 2017:

	<b>Unrestricted</b>	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>Total</b>
Donor-restricted endowment funds	\$ (200)	\$ 2,579,388	\$ 1,729,427	\$ 4,308,615
Board-designated endowment funds	2,561,567	215,848	-	2,777,415
Total endowment funds	<b>\$ 2,561,367</b>	<b>\$ 2,795,236</b>	<b>\$ 1,729,427</b>	<b>\$ 7,086,030</b>

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

(All amounts in thousands of dollars)

Changes in endowment net assets for the year ended June 30, 2017:

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
<b>Endowment net assets, beginning of year</b>	\$ 2,316,271	\$ 2,529,810	\$ 1,639,696	\$ 6,485,777
Investment return				
Net investment income	(2,655)	(2,062)	-	(4,717)
Net appreciation (realized and unrealized)	344,158	453,375	3,861	801,394
Total investment return	341,503	451,313	3,861	796,677
Gifts	179	1,826	67,764	69,769
Appropriation of endowment assets for expenditure	(131,648)	(173,942)	-	(305,590)
Net transfers of funds	84,459	10,333	14,743	109,535
Allocation of endowment return to treasurers investment pool	(55,668)	(18,008)	-	(73,676)
Reclassification of deficits in donor-designated funds	3,789	(3,789)	-	-
Other activity	2,482	(2,307)	3,363	3,538
<b>Endowment net assets, end of year</b>	<u>\$ 2,561,367</u>	<u>\$ 2,795,236</u>	<u>\$ 1,729,427</u>	<u>\$ 7,086,030</u>

Of the amount classified as temporarily restricted endowment net assets, \$2,265,185 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

**Permanently Restricted Net Assets**

The portion of perpetual endowment funds net assets that is required to be retained permanently by explicit donor stipulation:

	<u>2018</u>	<u>2017</u>
Restricted for general activities	\$ 1,218,398	\$ 1,166,424
Restricted for student assistance	437,987	388,046
Restricted for buildings and renovations	151,312	150,658
Life income	25,579	24,299
Total endowment net assets classified as permanently restricted net assets	<u>\$ 1,833,276</u>	<u>\$ 1,729,427</u>

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

---

*(All amounts in thousands of dollars)*

**Temporarily Restricted Net Assets**

Temporarily restricted endowment funds net assets:

	<b>2018</b>	<b>2017</b>
Restricted for general activities	\$ 2,017,498	\$ 1,874,381
Restricted for student assistance	536,114	462,794
Restricted for buildings and renovations	483,810	445,233
Life income	<u>12,139</u>	<u>12,828</u>
Total endowment net assets classified as temporarily restricted net assets	<u>\$ 3,049,561</u>	<u>\$ 2,795,236</u>

**Endowment Funds With Deficits**

As determined under UPMIFA, the fair value of assets associated with individual donor-restricted endowment funds may fall below the value of the initial and subsequent donor gift amounts (i.e., deficit). When donor endowment deficits exist, they are classified as a reduction of unrestricted net assets. Deficits of this nature reported in unrestricted net assets were immaterial as of June 30, 2018 and 2017, respectively. The deficits resulted largely from unfavorable market fluctuations that occurred shortly after the investment of newly established endowments.

**Return Objectives and Risk Parameters**

The university has adopted endowment investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. Under this policy, the return objective for the endowment assets, measured over a full market cycle, shall be to meet or exceed the return of its policy benchmark, based on the endowment's target allocation applied to the appropriate individual benchmarks. The university expects its endowment funds, over time, to provide an average rate of return that will exceed the sum of inflation and the spending rate. Actual returns in any given year may vary from this amount.

**Strategies Employed for Achieving Investment Objectives**

To achieve its long-term rate of return objectives, the university relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). The university targets a diversified global asset allocation that places greater emphasis on equity-based and alternative investments to achieve its long-term objectives within prudent risk constraints.

**Endowment Spending Allocation and Relationship of Spending Policy to Investment Objectives**

The university has an endowment spending distribution policy designed to stabilize annual spending levels and preserve the real value of the endowment over time. Under this policy, earnings of the pooled endowment are distributed at a rate set annually to the schools and other units of the university. Consideration is given to the provisions of UPMIFA in determining the amount to appropriate. This spending rate must fall within the range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For 2018, the spending rate from the pooled endowment was 4.5% of the beginning market value of the pooled endowment. The spending rate is funded from current earnings and, in years when current earnings are insufficient, from previously accumulated earnings of the endowment.

**Washington University**  
**Notes to the Consolidated Financial Statements**  
**June 30, 2018 and 2017**

---

*(All amounts in thousands of dollars)*

The university's endowment assets at June 30 are as follows:

	<b>Fair Market Value at June 30, 2018</b>	<b>Fair Market Value at June 30, 2017</b>
Pooled endowment and other funds	\$ 8,471,155	\$ 7,872,501
Life income trusts and pools	80,779	75,686
Externally administered trusts	32,123	37,040
Separately invested endowment	<u>7,085</u>	<u>6,512</u>
Total	8,591,142	7,991,739
Less: Operating funds invested in pool	<u>(903,750)</u>	<u>(776,781)</u>
Net endowment assets	<u>\$ 7,687,392</u>	<u>\$ 7,214,958</u>

**5. Accounts and Notes Receivable**

Accounts and notes receivable at June 30 were as follows:

	<b>2018</b>	<b>2017</b>
Patient services	\$ 398,705	\$ 327,044
Student and parent loans		
Parent loan fund	46,095	45,091
Government student loans	33,332	40,200
Institutional student loans	22,780	23,229
Due from affiliates	108,872	117,483
Sponsored project receivables	56,028	62,667
Other	<u>61,132</u>	<u>45,948</u>
	726,944	661,662
Less: Allowance for contractual adjustments and doubtful accounts	<u>(232,259)</u>	<u>(197,980)</u>
Total	<u>\$ 494,685</u>	<u>\$ 463,682</u>

The university is exposed to credit risk on amounts receivable from student and parent loans. Parent loan funds are offered by the university as a way for parents to finance their children's education at a fixed rate. Institutional student loans are offered by the university based on financial need. Both parent and institutional loans typically have ten year terms and, in the case of parent loans, existing economic conditions are evaluated annually in determining the interest rates for these loans. Government sponsored student loans carry minimal risk for the university.

# Washington University

## Notes to the Consolidated Financial Statements

### June 30, 2018 and 2017

(All amounts in thousands of dollars)

The principal credit quality indicator used by the university for the portfolio of nongovernment student and parent loans is collection experience. In order to reduce its credit risk, the university has adopted credit policies which include a review of credit limits and maintaining an active collections process with the assistance of third party collection agencies as necessary. At June 30, 2018, the allowance for parent and institutional student loans was \$4,377 compared to \$4,400 at June 30, 2017. Accounts are considered past due if a scheduled payment is thirty-one days late. The balance in such accounts was \$8,386 and \$7,569 at June 30, 2018 and June 30, 2017, respectively. Allowances are established based on management's best estimate of exposure at June 30 and are influenced by historical losses, existing economic conditions, and the current payment activity on loans. Activity in these allowances was not significant.

Parent loans and institutional student loans are sent to a third party collection agency if the loan is past due for a period of time and the university has been unable to collect payment. As these loans are non-dischargeable in bankruptcy, accounts are not typically considered uncollectible until all collection efforts have been exhausted with no receipt of payment. At this time, a loan will be written off.

## 6. Notes and Bonds Payable

Outstanding principal on bonds and notes payable at June 30, 2018 and 2017 consists of the following:

	Rates at June 30, 2018	Maturity	2018	2017
<b>Missouri Health and Educational Facilities Authority</b>				
\$142,400 of 1996A, B, C and D Series Variable Rate Bonds, due in full	.57% - 1.81%	September 1, 2030	\$ 142,400	\$ 142,400
\$88,000 of 2000B and C Series Variable Rate Bonds, due in full	.53% - 1.78%	March 1, 2040	88,000	88,000
\$25,135 of 2003B Series Variable Rate Bonds, due in full	.49% - 1.90%	February 15, 2033	25,135	25,135
\$22,985 of 2011A Series Revenue Bonds due in full	5.00%	November 15, 2041	22,985	22,985
\$96,350 of 2011B Series Revenue Bonds due in full November 15, 2030 (\$39,050) and November 15, 2037 (\$57,300)	5.00%	November 15, 2030 and 2037	96,350	96,350
\$77,495 of 2011C Series Revenue Bonds due serially from November 15, 2012 to November 15, 2037	.75% - 5.06%	November 15, 2037	57,740	61,215
\$200,785 of 2012A Series Revenue Bonds due serially from February 15, 2023 to February 15, 2047	2.39% - 3.69%	February 15, 2047	200,785	200,785
\$150,000 of 2014A Series Revenue Bonds due in full	4.07%	October 15, 2044	150,000	150,000
\$402,920 of 2016A Series Revenue Bonds due in full January 15, 2036 (\$109,300) and January 15, 2046 (\$293,620)	3.47% - 3.65%	January 15, 2036 and 2046	402,920	402,920
\$272,750 of 2016 B Series Revenue Bonds due in full	3.09%	September 15, 2051	272,750	272,750
\$375,000 of 2017 A Series Revenue Bonds, due in full	3.65%	August 15, 2057	375,000	-
<b>Other Bonds:</b>				
\$131,435 of 2015A Series Taxable Bonds due in full	3.79%	October 15, 2055	131,435	131,435
Other notes payable			68,798	39,816
Total outstanding notes and bonds payable			2,034,298	1,633,791
Unamortized original issue premiums/discounts and cost of issuance, net			(3,517)	(1,589)
Total			<u>\$ 2,030,781</u>	<u>\$ 1,632,202</u>

# Washington University

## Notes to the Consolidated Financial Statements

### June 30, 2018 and 2017

---

*(All amounts in thousands of dollars)*

Bonds payable are redeemable at the option of the university at various times from 2018 through 2057. The university is required to maintain certain ratios and comply with other restrictive covenants principally that the university maintain a ratio of expendable financial resources to debt of at least 1.25 times. The university is in compliance with this covenant. During 2018 and 2017, interest, accretion of debt discount and related fees incurred on notes and bonds payable totaled \$67,862 and \$54,036, respectively.

Maturities on notes and bonds payable for the next five fiscal years are as follows:

2019	\$	17,273
2020		2,470
2021		57,199
2022		2,380
2023		22,475
Thereafter		1,932,501

During fiscal 2018, the university issued \$375,000 of taxable Series 2017A Missouri Health and Educational Facilities Authority (MOHEFA) bonds. The bonds bear a fixed rate of 3.652% and will mature on August 15, 2057. The proceeds of these bonds will be used to finance various construction projects.

During fiscal 2017, the university issued \$272,750 of taxable Series 2016B bonds \$243,395 of net proceeds from the issuance and other funds were placed in an irrevocable trust to be used to satisfy all interest and principal payments, including principal to be paid at the first scheduled call date, for \$149,625 of the 2008 Series A MOHEFA Bonds and \$93,770 of the 2009 Series A MOHEFA Bonds. In accordance with the terms of the MOHEFA Bond indentures and loan agreements, establishment of the trust results in the legal defeasance of the university's obligation under the bonds. The transaction was accounted for as an extinguishment with a recognized loss of \$23,980 reported on the Gain (Loss) on fixed asset disposals and other line of the Consolidated Statements of Activities.

The university has other lines of credit, which generally expire annually, aggregating \$298,500, of which \$243,595 is available at June 30, 2018. The university expects that these lines of credit will be renewed but can make no assurances.

## **7. Derivative and Other Financial Instruments**

The University utilizes derivative instruments including futures, swaps, and options, to manage market risk, to provide temporary investment exposure in stocks and bonds, and to manage currency and interest rate exposures. When directly implementing a derivative strategy, the University uses a third party manager to execute, settle and manage the positions on a nondiscretionary basis. These contracts are valued at periodic intervals such as daily, monthly, and quarterly as well as at June 30, with the resulting changes in the values of the contracts either added to or deducted from the University's custodial account. Gains or losses from these derivative instruments are reported as realized and unrealized gains or losses in the Consolidated Statements of Activities. Indirect strategies in derivatives held by limited partnerships and commingled investment trusts in which the University invests pose no off-balance sheet risk to the University due to the limited liability structure of the investments. Derivatives are also used to manage

# Washington University

## Notes to the Consolidated Financial Statements

### June 30, 2018 and 2017

---

*(All amounts in thousands of dollars)*

operating expenses but are not material to the consolidated financial statements. No derivative contracts are designated as hedges for accounting purposes.

#### **8. Commitments and Contingencies**

At June 30, 2018, the university had outstanding commitments under certain construction contracts in the amount of \$190,356.

The university maintains a self-insurance program for professional liability at the Medical School and a separate program for Washington University Physicians in Illinois. This program is supplemented with commercial excess insurance above the university's self-insurance retention. Funding for the program reserves is based on claims made. The assets supporting the funded reserve are reported as investments in the Consolidated Statements of Financial Position. The university also accrues for an estimate of claims incurred but not reported. Reserves, funded and unfunded, are based upon actuarial studies and represent undiscounted estimated claims and related costs. The total self-insurance reserves at June 30, 2018 and 2017, respectively, were \$73,756 and \$69,106. Self-insurance reserves are necessarily estimates based on historical loss experience and other factors, and while management believes that the reserves are adequate, the ultimate liabilities may be in excess of or less than the amounts provided.

The university is a party, along with other universities, to an agreement with a reciprocal risk retention group for purposes of obtaining general liability and auto liability insurance coverage in excess of a pre-determined retention level. Under the terms of these agreements, the university can be called upon to make additional capital contributions. In management's view, any such capital calls would not be material.

The university is involved in various legal proceedings arising in the normal course of operations. Although the outcome of any legal proceeding cannot be predicted with certainty, it is the opinion of the university's management that the outcome of these proceedings individually or in the aggregate, will not have a material adverse effect on the business, Consolidated Statements of Activities, financial position or liquidity of the university.

#### **9. Retirement Plan**

The university provides its faculty and staff with a defined contribution (403(b)) retirement savings plan in which employee contributions, university contributions and investment earnings accumulate to assist employees at retirement. Participating employees own individual retirement accounts through the Teachers Insurance and Annuity Association (TIAA) and College Retirement Equity Fund (CREF). Under this arrangement, the university and plan participants make monthly contributions to TIAA-CREF. For employees who were benefits eligible as of August 31, 2006, the amount of contribution made by the university, commencing after two years of eligible service, is based upon the employee's age and salary. For benefits-eligible employees hired or rehired after August 31, 2006, the university contribution commences after two years of eligible service and is based upon the employee's years of eligible service and salary. Vesting provisions are full and immediate. The university's share of the cost of these benefits in 2018 and 2017 was \$82,065 and \$75,739, respectively.

# Washington University

## Notes to the Consolidated Financial Statements

### June 30, 2018 and 2017

---

*(All amounts in thousands of dollars)*

#### **10. Agreements With Affiliated Hospitals**

The university has affiliation agreements, extended during fiscal 2018 to December 31, 2027, with Barnes Jewish Hospital (BJH) and St. Louis Children's Hospital (SLCH), collectively the Hospitals. This includes operating activities of Barnes Jewish Hospital at Barnes Jewish West County Hospital (BJWCH), Barnes Jewish Orthopedic Center (OC) in Chesterfield, the Siteman Cancer Center – South County, and the Children's Specialty Care Center in Town and Country.

The terms of the affiliation agreements provide for the university to be responsible for providing professional medical staff and direction, supervision of residents and interns, appropriate resources for research and medical education, and participation in joint clinical planning. BJH and SLCH are responsible for the hospitals and health care delivery facilities. BJH and SLCH compensate the university for services provided by the university through a fixed annual base payment (adjusted annually for inflation) and an additional contingent payment equal to a share of the combined BJH and SLCH adjusted net operating income. The combined compensation payments are reported as Affiliated hospital revenue on the Consolidated Statements of Activities. In addition, the university derives revenue from patient services provided at Barnes-Jewish at St. Peters Hospital under an agreement with that hospital and BJH. During 2013, BJH agreed to fund on a cost-reimbursement basis over a period of years, certain expenditures by the university. Payments of \$37,941 and \$34,483 were received or accrued as gifts on the Consolidated Statements of Activities under the agreement during 2018 and 2017, respectively.

#### **11. Subsequent Events**

The university has performed an evaluation of subsequent events through September 25, 2018, which is the date the consolidated financial statements were issued.



## **Supplementary Information**

# Washington University

## Schedule of Expenditures of Federal Awards

### For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients		
<b>Research and Development Cluster</b>							
<b>DEPARTMENT OF DEFENSE</b>							
<b>Advanced Research Projects Agency</b>							
Research and Technology Development	12.910	Vanderbilt University Medical Center	HR00111820001	\$ 1,458,885	\$ -		
Research and Technology Development	12.910			298,511	-		
<b>Defense Advanced Research Projects Agency</b>							
Defense Advanced Research Projects Agency	12	Two Six Labs	HR00117C011	400,120	-		
Defense Advanced Research Projects Agency	12	Raytheon BBN Technologies	HR001117C0049	65,605	-		
<b>Defense Threat Reduction Agency</b>							
Basic Scientific Research - Combating Weapons of Mass Destruction	12.351	Georgia State University	HDTRA11710005	1,554,019	782,021		
Basic Scientific Research - Combating Weapons of Mass Destruction	12.351			52,865	-		
Basic Scientific Research - Combating Weapons of Mass Destruction	12.351			215,052	-		
<b>Department of the Air Force, Material Command</b>							
Air Force Defense Research Sciences Program	12.800	UES, INC.	FA865015D5405	943,300	77,508		
Air Force Defense Research Sciences Program	12.800			50,679	-		
<b>Department of the Navy, Office of the Chief of Naval Research</b>							
Basic and Applied Scientific Research	12.300	University of California, Davis	N000141712961	2,088,799	-		
Basic and Applied Scientific Research	12.300			163,007	-		
<b>U.S. Army</b>							
U.S. Army	12	CFD Research Corporation	W911QY17C0008	136,014	-		
U.S. Army	12	University of Minnesota		61	-		
<b>U.S. Army Material Command</b>							
Basic Scientific Research	12.431	Georgia Institute of Technology	W911NF1310244	182,623	-		
Basic Scientific Research	12.431			62,490	-		
Basic Scientific Research	12.431			30	-		
Basic Scientific Research	12.431			30,790	-		
Basic Scientific Research	12.431			54,299	-		
<b>U.S. Army Medical Command</b>							
Military Medical Research and Development	12.420	Brigham and Women's Hospital	W81XWH1510269	6,501,196	161,527		
Military Medical Research and Development	12.420			27,387	-		
Military Medical Research and Development	12.420			2,460	-		
Military Medical Research and Development	12.420			1,500	-		
Military Medical Research and Development	12.420			75,129	-		
Military Medical Research and Development	12.420			5,214	-		
Military Medical Research and Development	12.420			106,002	-		
Military Medical Research and Development	12.420			(32)	-		
Military Medical Research and Development	12.420			33,221	-		
Military Medical Research and Development	12.420			51,567	-		
Military Medical Research and Development	12.420			13,530	-		
Military Medical Research and Development	12.420			5,007	-		
Military Medical Research and Development	12.420			1,973	-		
Military Medical Research and Development	12.420			7,041	-		
Military Medical Research and Development	12.420			5,211	-		
Military Medical Research and Development	12.420			670	-		
TOTAL DEPARTMENT OF DEFENSE						<u>14,594,224</u>	<u>1,021,056</u>

The accompanying notes are an integral part of this schedule.

# Washington University

## Schedule of Expenditures of Federal Awards

### For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
<b>DEPARTMENT OF EDUCATION</b>					
<b>Institute of Education Sciences</b>					
Education Research, Development and Dissemination	84.305	Duke University	R305A130535	66,294	-
<b>National Institute on Disability and Rehabilitation Research</b>					
Switzer Research Fellowship Program	84.133	Gallaudet University	90RE50200201	23,656	-
<b>Office of Postsecondary Education</b>					
Overseas Programs - Doctoral Dissertation Research Abroad	84.022			14,190	-
Graduate Assistance in Areas of National Need	84.200			183,149	-
<b>Office of Special Education and Rehabilitative Services</b>					
Special Education - Personnel Development to Improve Services and Results for Children with Disabilities	84.325			418,166	-
Special Education - Personnel Development to Improve Services and Results for Children with Disabilities	84.325	Salus University	H325H14000216	<u>149,300</u>	-
TOTAL DEPARTMENT OF EDUCATION				<u>854,755</u>	-
<b>DEPARTMENT OF ENERGY</b>					
<b>Department of Energy</b>					
Office of Science Financial Assistance Program	81.049			6,844,390	2,084,029
Office of Science Financial Assistance Program	81.049	Georgia Tech	DESC0012577	86,080	-
Office of Science Financial Assistance Program	81.049	Smithsonian Institute	DE-FG02-91ER40635	15,047	-
Renewable Energy Research and Development	81.087			962,867	554,429
Renewable Energy Research and Development	81.087	University of Missouri, St. Louis.	DEEE0007656	20,654	-
Renewable Energy Research and Development	81.087	West Virginia Research Corporation	DEP10000017	249,296	-
Fossil Energy Research and Development	81.089			702,630	68,747
Fossil Energy Research and Development	81.089	University of Illinois, Urbana-Champaign	DEFEO029161	149,848	-
Fossil Energy Research and Development	81.089	Electric Power Research Institute	10007331	294,893	-
Stewardship Science Grant Program	81.112	Carnegie Institution of Washington	DENA0020006	33,647	-
Advanced Research Projects Agency - Energy	81.135			595,081	114,023
Advanced Research Projects Agency - Energy	81.135	Danforth Plant Science Center	DEAR0000594	1,966	-
Department of Energy	81			30,734	-
Department of Energy	81	Alliance for Sustainable Energy, LLC National Renewable Energy Laboratory	DEAC3609GO28308	85,890	-
Department of Energy	81	Linde LLC	DEFEO031592	11,159	-
Department of Energy	81	Proton Energy Systems, Inc.	DESC0007574	69,975	-
Department of Energy	81	Sandia National Labs	DENA0003525	11,605	-
Department of Energy	81	University of California, Lawrence Berkley National Laboratory	DEAC0205CH11231	<u>211,084</u>	-
TOTAL DEPARTMENT OF ENERGY				<u>10,376,847</u>	<u>2,821,228</u>
<b>DEPARTMENT OF HEALTH AND HUMAN SERVICES</b>					
<b>Administration for Children and Families</b>					
State Court Improvement Program	93.586			85,448	-
Head Start	93.600			86,474	-
Social Services Research and Demonstration	93.647			6,084	-
Child Abuse and Neglect Discretionary Activities	93.670			285,726	1,572
<b>Administration for Community Living</b>					
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433			186,463	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	University of Kansas Center for Research	90RT20150202	42,060	-
State Grants for Protection and Advocacy Services	93.873			621	-

The accompanying notes are an integral part of this schedule.

# Washington University

## Schedule of Expenditures of Federal Awards

### For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
<b>Agency for Healthcare Research and Quality</b>					
Research on Healthcare Costs, Quality and Outcomes	93.226			1,691,285	16,704
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Maryland	1R01HS02545601	18,501	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Maryland	5R01HS02545602	2,532	-
<b>Centers for Disease Control</b>					
Birth Defects and Developmental Disabilities - Prevention and Surveillance	93.073			488,937	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084			1,750,631	685,900
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Duke University	5U54CK00048302	86,518	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Harvard Pilgrim Healthcare	5U54CK00048402	110,187	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	University of Pennsylvania	5U54CK00048502	267,846	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Rush University	6U54CK00048102	(5)	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Rush University	6U54CK00048103	22,373	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Rush University	5U54CK00048103	16,681	-
Centers for Research and Demonstration for Health Promotion and Disease Intervention	93.135	University Of South Florida	5U48DP00502403	7,573	-
Occupational Safety and Health Program	93.262			284,715	-
Occupational Safety and Health Program	93.262	Applied Particle Technology, LLC	1R43OH01149901	4,700	-
Occupational Safety and Health Program	93.262	Center For Construction Research & Training	5U60OH00976208	47,136	-
Occupational Safety and Health Program	93.262	Center For Construction Research & Training	5U60OH00976209	180,290	-
Occupational Safety and Health Program	93.262	University of Iowa	2U19OH00886811	51,604	-
Occupational Safety and Health Program	93.262	University of Iowa	5U10OH00886812	178,874	-
Centers for Disease Control and Prevention, Investigations and Technical Assistance	93.283			683,032	277,221
National Organizations for Chronic Disease Prevention and Health Promotion	93.809	National Association For Chronic Disease Director	5NU58DP0061280200	133,436	-
Preventive Health Services	93.977			386,046	4,477
Centers for Disease Control	93			120,916	-
Centers for Disease Control	93	Healthcore, Inc.	200201142070004	485,610	-
Centers for Disease Control	93	Healthcore, Inc.	200201142070	35,932	-
<b>Centers for Medicare and Medicaid Services</b>					
Pre-existing Condition Insurance Program	93.529	University of Colorado, Denver	2R01GM10022505	1,713	-
Pre-existing Condition Insurance Program	93.529	University of Colorado, Denver	5R01GM10022506	16,134	-
Health Care Innovation Awards (HCIA)	93.610			745,290	-
<b>Food and Drug Administration</b>					
Food and Drug Administration_Research	93.103			84,601	-
Food and Drug Administration_Research	93	University of Southern California	HHSF223201400115C	25,352	-
<b>Health Resources and Services Administration</b>					
Grants to Increase Organ Donations	93.134	Johns Hopkins University	1R39OT311030100	8,033	-
Rural Health Research Centers	93.155	University of Iowa	5U1CRH2041909	152,510	-
Rural Health Research Centers	93.155	University of Iowa	6U1CRH204190803	27,401	-
Rural Health Research Centers	93.155	University of Iowa	6U1GRH076331000	39,015	-
<b>National Institutes of Health</b>					
Environmental Health	93.113			2,760,642	415,657
Environmental Health	93.113	Baylor College of Medicine	5U01ES02671903	38,060	-
Environmental Health	93.113	Johns Hopkins University	5R01ES02696102	53,717	-
Oral Diseases and Disorders Research	93.121			1,346,726	142,570
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	University of Louisville	5P42ES02371602	19,701	-

The accompanying notes are an integral part of this schedule.

# Washington University

## Schedule of Expenditures of Federal Awards

### For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Human Genome Research	93.172			18,226,623	1,434,950
Human Genome Research	93.172	California Institute of Technology	U41HG002223D	4,490	-
Human Genome Research	93.172	California Institute of Technology	5U41HG00222318	39,391	-
Human Genome Research	93.172	Ecog-Acrin Cancer Research Group	5U10CA18082004	6,601	-
Human Genome Research	93.172	Ecog-Acrin Cancer Research Group	5U10CA18082005	3,333	-
Human Genome Research	93.172	Jackson Laboratory	5U41HG00749704	11,056	-
Human Genome Research	93.172	Nationwide Children's Hospital	3U41HG00763504S1	228,179	-
Human Genome Research	93.172	Nationwide Children's Hospital	7U41HG00763504	55,985	-
Human Genome Research	93.172	Nawgen, LLC	5R41HG00856702	68,388	-
Human Genome Research	93.172	Stanford University	1UM1HG00944201	229,540	-
Research Related to Deafness and Communication Disorders	93.173			6,829,396	562,323
Research Related to Deafness and Communication Disorders	93.173	Barron Associates, Inc.	5R44DC01008003	21,430	-
Research Related to Deafness and Communication Disorders	93.173	Father Flanagan's Boys Home	5R01DC01538502	152,070	-
Research Related to Deafness and Communication Disorders	93.173	Jackson Laboratory	5R01DC00430118	62,486	-
Research Related to Deafness and Communication Disorders	93.173	Temple University	5R01DC01306304	17,133	-
Research Related to Deafness and Communication Disorders	93.173	Temple University	5R01DC01306305	12,180	-
Research Related to Deafness and Communication Disorders	93.173	University of Alabama	1R01DC01598001A1	96,214	-
Research Related to Deafness and Communication Disorders	93.173	University of Kansas	5R01DC00180322	48,845	-
Research Related to Deafness and Communication Disorders	93.173	University of Kansas	5R01DC00180323	36,812	-
Research Related to Deafness and Communication Disorders	93.173	University of Michigan	1R01DC01580901	4,310	-
Research Related to Deafness and Communication Disorders	93.173	University of Nevada, Reno	5P01AG05144303	13,624	-
Research Related to Deafness and Communication Disorders	93.173	University of Nevada, Reno	1P01AG05144301A1	259	-
Research Related to Deafness and Communication Disorders	93.173	University of Nevada, Reno	1R01DC01513501A1	10,076	-
Research Related to Deafness and Communication Disorders	93.173	University of Nevada, Reno	1R01DC01609901	35,457	-
Research Related to Deafness and Communication Disorders	93.173	University of Nevada, Reno	5P01AG05144302	106,205	-
Research Related to Deafness and Communication Disorders	93.173	University of Nevada, Reno	5R01DC01513502	55,984	-
Research Related to Deafness and Communication Disorders	93.173	University of Virginia	5R01DC01425403	9,828	-
Research and Training in Complementary and Integrative Health	93.213			348,331	-
Mental Health Research Grants	93.242			23,240,002	5,282,295
Mental Health Research Grants	93.242	Columbia University	1P50MH10942901A1	97,974	-
Mental Health Research Grants	93.242	Emory University	1R01MH11469201	22,715	-
Mental Health Research Grants	93.242	Emory University	5R01MH11469202	8,366	-
Mental Health Research Grants	93.242	Icahn School of Medicine Mount Sinai	5R25MH080663	19,223	-
Mental Health Research Grants	93.242	Indiana University	5R01MH10846703	114,476	-
Mental Health Research Grants	93.242	NeuroLux, Inc.	1R44MH11494401	153,912	-
Mental Health Research Grants	93.242	Northwestern University	4U01MH09743504	20,075	-
Mental Health Research Grants	93.242	Research Foundation for Mental Hygiene	1P50MH11584301	17,897	-
Mental Health Research Grants	93.242	Rutgers University	2U24MH06845715	19,143	-
Mental Health Research Grants	93.242	Rutgers University	5U24MH06845715	352,632	-
Mental Health Research Grants	93.242	Scripps Research Institute	5R01MH10269804	208,875	-
Mental Health Research Grants	93.242	Scripps Research Institute	5R01MH10269805	28,088	-
Mental Health Research Grants	93.242	The State University of New York	5U01HL13155203	65,827	-
Mental Health Research Grants	93.242	The State University of New York	1U01HL13155201	477	-
Mental Health Research Grants	93.242	The State University of New York	5U01HL13155202	659,047	-
Mental Health Research Grants	93.242	The Miriam Hospital	1R01MH11465701	30,480	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Mental Health Research Grants	93.242	University of California, Los Angeles	4R01MH10002710	227,293	-
Mental Health Research Grants	93.242	University of California, San Diego	5R01MH10734503	98,236	-
Mental Health Research Grants	93.242	University of Missouri, St. Louis.	R01MH108559	114,428	-
Mental Health Research Grants	93.242	University of North Carolina, Chapel Hill	5U01MH11092502	6,495	-
Mental Health Research Grants	93.242	University of South Florida	5D43MH10816903	9,029	-
Mental Health Research Grants	93.242	University of Washington	5R01MH10854802	9,317	-
Mental Health Research Grants	93.242	Yale University	1R01MH11274601A1	32,041	-
Mental Health Research Grants	93.242	Yale University	5R01MH10859002	54,751	-
Alcohol Research Programs	93.273			1,081,758	89,363
Alcohol Research Programs	93.273	Research Foundation For The State University of New York	2U10AA00840126	(160)	-
Alcohol Research Programs	93.273	Research Foundation For The State University of New York	5U10AA00840128	213,692	-
Alcohol Research Programs	93.273	Research Foundation For The State University of New York	5U10AA00840129	873,505	-
Alcohol Research Programs	93.273	University of Illinois, Urbana-Champaign	7R01AA02410303	4,930	-
Alcohol Research Programs	93.273	Yale University	5R01AA02354904	66,306	-
Drug Abuse and Addiction Research Programs	93.279			7,939,328	267,143
Drug Abuse and Addiction Research Programs	93.279	RTI International	1R01DA04209003	11,519	-
Drug Abuse and Addiction Research Programs	93.279	RTI International	1R01DA04401401	25,016	-
Drug Abuse and Addiction Research Programs	93.279	RTI International	5R01DA03863204	73,591	-
Drug Abuse and Addiction Research Programs	93.279	RTI International	5R01DA03582502	(6,478)	-
Drug Abuse and Addiction Research Programs	93.279	University of Iowa	5R01DA03764804	21,128	-
Drug Abuse and Addiction Research Programs	93.279	University of Minnesota	5U01DA04112002	15,429	-
Drug Abuse and Addiction Research Programs	93.279	University of Minnesota	5U01DA04112003	1,624,533	-
Drug Abuse and Addiction Research Programs	93.279	University of Minnesota	5U01DA04112004	141,534	-
Drug Abuse and Addiction Research Programs	93.279	Virginia Commonwealth University	5R01DA02142109	5,665	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286			3,838,463	603,573
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cornell University	1R21EB02436601	13,501	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cornell University	5R21EB02436602	10,963	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Kitware, Inc.	5R01EB02139602	17,384	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Massachusetts	1U01EB02195601	2,556	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Massachusetts	5U01EB02195602	237,802	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Pittsburgh	5R01EB01913504	70,390	-
Minority Health and Health Disparities Research	93.307			627,657	-
Minority Health and Health Disparities Research	93.307	University of Pittsburgh	5R01MD000911804	12,076	-
Trans-NIH Research Support	93.310			1,946,826	231,357
Trans-NIH Research Support	93.310	Brigham and Women's Hospital	5UGOD02326802	31,662	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital	1UGOD02326801	3,377	-
Trans-NIH Research Support	93.310	California Institute of Technology	7R01CA18656705	50,355	-
Trans-NIH Research Support	93.310	Drexel University	1UG3OD02334201	13,228	-
Trans-NIH Research Support	93.310	Drexel University	5UG3OD02334202	58,473	-
Trans-NIH Research Support	93.310	The Broad Institute	3U54DK10257703	2,335	-
Trans-NIH Research Support	93.310	University of North Carolina, Chapel Hill	1U24DK11620401	247,292	-
Trans-NIH Research Support	93.310	University of Wisconsin, Madison	1UG3OD02328201	6,993	-
Trans-NIH Research Support	93.310	University of Wisconsin, Madison	5UG3OD02328202	185,535	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
National Center for Advancing Translational Sciences	93.350			13,981,248	688,226
National Center for Advancing Translational Sciences	93.350	Dystonia Coalition - Emory	U54TR001456	1,631	-
National Center for Advancing Translational Sciences	93.350	Oregon Health & Science University	1U24TR00230601	286,123	-
National Center for Advancing Translational Sciences	93.350	University of Pittsburgh	5UL1TR00185702	74,644	-
National Center for Advancing Translational Sciences	93.350	Yale University	ULTR00186302S2	134,928	-
Research Infrastructure Programs	93.351			3,990,670	550,563
Research Infrastructure Programs	93.351	Texas State University	5R24OD01112010	88,925	-
Research Infrastructure Programs	93.351	University of Oregon	5R24OD01855505	25,022	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353			2,059,271	528,438
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Fred Hutchinson Cancer Research	2UM1CA15496707	2,924	-
Nursing Research	93.361			2,096,441	180,434
Nursing Research	93.361	Barnes Jewish Hospital	1R15NR01682801A1	9,940	-
Nursing Research	93.361	Brightoutcome Inc.	5R44NR01618303	127,731	-
Nursing Research	93.361	University of California, San Francisco	5R01NR01522305	123,649	-
Nursing Research	93.361	University of Pittsburgh	5R01NR01422104	15,121	-
ACL Independent Living State Grants	93.369	University of Iowa	5R01CA17474306	87,757	-
Cancer Cause and Prevention Research	93.393			4,515,551	409,731
Cancer Cause and Prevention Research	93.393	Baylor University	1U19CA20365401A1	12,036	-
Cancer Cause and Prevention Research	93.393	Dartmouth College	1U19CA20365401A1	5,851	-
Cancer Cause and Prevention Research	93.393	Emory University	5U01CA15428205	(68)	-
Cancer Cause and Prevention Research	93.393	Health Communication Impact	1R44CA19244201	14,376	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	1U01CA19556802	93,140	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	5U01CA19556804	26	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan Kettering Cancer Center	1R01CA22323101A1	5,001	-
Cancer Cause and Prevention Research	93.393	Northwestern University	1R01CA21843601	14,577	-
Cancer Cause and Prevention Research	93.393	Ohio State University	5P01CA10073013	213,744	-
Cancer Cause and Prevention Research	93.393	Ohio State University	5P01CA10073014	362,376	-
Cancer Cause and Prevention Research	93.393	Research Foundation For The State University of New York	5R01CA19735103	32,178	-
Cancer Cause and Prevention Research	93.393	Stanford University	5R01CA19369402	27,993	-
Cancer Cause and Prevention Research	93.393	University of California, San Francisco	5R01CA18568703	13,642	-
Cancer Cause and Prevention Research	93.393	University of Iowa	5R01CA19324902	156,704	-
Cancer Cause and Prevention Research	93.393	University of North Carolina	5U01CA1528105	13,511	-
Cancer Cause and Prevention Research	93.393	University of Utah	1U01CA20611001	31,460	-
Cancer Cause and Prevention Research	93.393	University of Utah	5U01CA20611002	203,502	-
Cancer Detection and Diagnosis Research	93.394			7,820,691	2,172,856
Cancer Detection and Diagnosis Research	93.394	Boston University	5R01CA20859902	4,042	-
Cancer Detection and Diagnosis Research	93.394	Case Western Reserve University	5R21CA17932702	(7,349)	-
Cancer Detection and Diagnosis Research	93.394	Johns Hopkins University	5U01CA14020405	39,594	-
Cancer Detection and Diagnosis Research	93.394	New York University School of Medicine	1U24CA21097201	65,695	-
Cancer Detection and Diagnosis Research	93.394	New York University School of Medicine	5U24CA21097202	166,391	-
Cancer Detection and Diagnosis Research	93.394	Princeton University	1U24CA21100001	2,112	-
Cancer Detection and Diagnosis Research	93.394	Princeton University	5U24CA21100002	8,217	-
Cancer Detection and Diagnosis Research	93.394	University of Arkansas Health Sciences	5U01CA18701304	7,899	-
Cancer Detection and Diagnosis Research	93.394	University of Arkansas Health Sciences	5U01CA18701305	26,975	-
Cancer Detection and Diagnosis Research	93.394	University of California, San Francisco	1R01CA21214801	247,558	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Cancer Detection and Diagnosis Research	93.394	University of Colorado, Denver	5U01CA15771505	27,186	-
Cancer Detection and Diagnosis Research	93.394	University of Illinois	4R01CA02583636	60,372	-
Cancer Detection and Diagnosis Research	93.394	University of Pittsburgh	5U01CA20046602	51,141	-
Cancer Detection and Diagnosis Research	93.394	University of Pittsburgh	5U01CA20046603	19,045	-
Cancer Treatment Research	93.395			8,483,257	531,917
Cancer Treatment Research	93.395	Altor Bioscience Corporation	1R44CA19581201A1	85,419	-
Cancer Treatment Research	93.395	American College of Radiology	5U24CA18080304IROC	194,662	-
Cancer Treatment Research	93.395	Brigham & Women's Hospital	3U10CA18082103	189,692	-
Cancer Treatment Research	93.395	Brigham & Women's Hospital	3U10CA18082104S1	34,507	-
Cancer Treatment Research	93.395	Brigham & Women's Hospital	U10CA180821	10,493	-
Cancer Treatment Research	93.395	Children's Hospital of Philadelphia	5U10CA18088604	117,234	-
Cancer Treatment Research	93.395	Children's Hospital of Philadelphia	UM1CA097452	5,669	-
Cancer Treatment Research	93.395	Children's Hospital of Philadelphia	5U10CA18088603	61,223	-
Cancer Treatment Research	93.395	Children's Hospital of Philadelphia	5UM1CA09745214	11,916	-
Cancer Treatment Research	93.395	Children's Hospital of Philadelphia	1UG1CA18995501	35,995	-
Cancer Treatment Research	93.395	Children's Hospital of Philadelphia	5U10CA18088604	30,292	-
Cancer Treatment Research	93.395	Children's Hospital of Philadelphia	3U10CA1808860227	14,728	-
Cancer Treatment Research	93.395	Children's Hospital of Philadelphia	1U10CA18088601	34,185	-
Cancer Treatment Research	93.395	Doseimaging, LLC	1R41CA20298001A1	89,402	-
Cancer Treatment Research	93.395	Duke University	3UM1CA18670403S1	124,981	-
Cancer Treatment Research	93.395	Duke University	5UM1CA18670402	47,212	-
Cancer Treatment Research	93.395	Duke University	5UM1CA18670403	165,579	-
Cancer Treatment Research	93.395	Ecog-Acrin Medical Research Foundation	5U10CA18082004	30,539	-
Cancer Treatment Research	93.395	Ecog-Acrin Medical Research Foundation	5U10CA18082005	11,179	-
Cancer Treatment Research	93.395	Ecog-Acrin Medical Research Foundation	PDS137629	90,715	-
Cancer Treatment Research	93.395	Fred Hutchinson Cancer Research Center	5U01CA15496706	(2,431)	-
Cancer Treatment Research	93.395	Illinois Institute of Technology	5R01CA11250308	13,716	-
Cancer Treatment Research	93.395	Johns Hopkins University	5UM1CA13744307	5,848	-
Cancer Treatment Research	93.395	Massachusetts General Hospital	1U01NS9366301A1	11,882	-
Cancer Treatment Research	93.395	Medical Guidance Systems	1R41CA19600201A1	(2,389)	-
Cancer Treatment Research	93.395	Medical Guidance Systems	1R43CA21068701	5,145	-
Cancer Treatment Research	93.395	NRG Oncology Foundation	5U10CA18086804	24,430	-
Cancer Treatment Research	93.395	NRG Oncology Foundation	5U10CA18086805	5,015	-
Cancer Treatment Research	93.395	NRG Oncology Foundation	1U10CA1808601	7,122	-
Cancer Treatment Research	93.395	Protexase	1R43CA22483201A1	7,439	-
Cancer Treatment Research	93.395	Sloan Kettering Institute	5R01CA18255105	(495)	-
Cancer Treatment Research	93.395	University of California, Los Angeles	2UM1CA12194709	125,183	-
Cancer Treatment Research	93.395	University of California, San Diego	4P01CA08153416	4,211	-
Cancer Treatment Research	93.395	University of Minnesota	5P01CA1141212	19,868	-
Cancer Treatment Research	93.395	University of Pennsylvania	5R01CA19733203	3,317	-
Cancer Treatment Research	93.395	University of Rochester	1R01CA21489001A1	14,943	-
Cancer Treatment Research	93.395	Virginia Commonwealth University	1R01CA14930505	23,941	-
Cancer Biology Research	93.396			7,428,391	142,296

The accompanying notes are an integral part of this schedule.



# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Cancer Biology Research	93.396	Dana-Farber Cancer Institute	5R01CA1309880608	3,175	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute	5R01CA13098809	58,231	-
Cancer Biology Research	93.396	Emory University	5U01CA16088205	15,279	-
Cancer Biology Research	93.396	University of Iowa	7R01CA17474305	5,137	-
Cancer Biology Research	93.396	University of Texas M.D Anderson Cancer Center	5R01CA17265204	52,076	-
Cancer Biology Research	93.396	University of Wisconsin, Madison	5R01CA18729904	15,044	-
Cancer Center Support Grants	93.397			11,890,030	1,015,066
Cancer Center Support Grants	93.397	Case Western Reserve University	2U54CA16306006	42,827	-
Cancer Center Support Grants	93.397	Case Western Reserve University	2U54CA16306007	7,177	-
Cancer Center Support Grants	93.397	Johns Hopkins University	5U54CA21017302	132,340	-
Cancer Center Support Grants	93.397	Sarcoma Alliance	U54CA16851204	18,301	-
Cancer Center Support Grants	93.397	Sarcoma Alliance	U54CA16851205	11,971	-
Cancer Research Manpower	93.398			3,982,491	-
Cancer Control	93.399			221,555	16,715
Trans-NIH Recovery Act Research Support	93.701	University of South Alabama	R01CA164940	82	-
Alzheimer's Disease Initiative	93.763	Memory Home Care Solutions	90ALGG00210100	12,899	-
Cardiovascular Diseases Research	93.837			22,779,971	1,876,096
Cardiovascular Diseases Research	93.837	Albert Einstein College of Medicine	5R01HL12807105	119,869	-
Cardiovascular Diseases Research	93.837	Auxagen, Inc.	1R43HL13267901	38,937	-
Cardiovascular Diseases Research	93.837	Boston Children's Hospital	2R01HL10810705	122,761	-
Cardiovascular Diseases Research	93.837	Brigham & Women's Hospital	5U01HL10142203	20,364	-
Cardiovascular Diseases Research	93.837	Brigham & Women's Hospital	5P50HL11234905	21,592	-
Cardiovascular Diseases Research	93.837	Brigham & Women's Hospital	5U01HL13016303	1,341	-
Cardiovascular Diseases Research	93.837	Capella Imaging LLC	1R42HL13934201	200,112	-
Cardiovascular Diseases Research	93.837	Children's Hospital Medical Center	5R24HL10533305	552	-
Cardiovascular Diseases Research	93.837	Children's Hospital of Philadelphia	5R01HL13154403	22,113	-
Cardiovascular Diseases Research	93.837	Com Affiliation Inc.	5R01HL12807103	21,403	-
Cardiovascular Diseases Research	93.837	Com Affiliation Inc.	5R01HL12807104	185,253	-
Cardiovascular Diseases Research	93.837	Duke University	5U10HL08490408	31,019	-
Cardiovascular Diseases Research	93.837	Duke University	R01HL105448	1,545	-
Cardiovascular Diseases Research	93.837	Harvard Pilgrim Healthcare	5R01HL11548505	39,261	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL13864602	153,294	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL12333603	90,422	-
Cardiovascular Diseases Research	93.837	Medical College of Wisconsin	5R01HL12558002	77,854	-
Cardiovascular Diseases Research	93.837	Medical College of Wisconsin	5R01HL12558009	70,728	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	1U24HL138660	5,833	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	5U01HL10913702	360	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	1U10HL10913701	1,000	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	4U10HL06929416	3,501	-
Cardiovascular Diseases Research	93.837	New England Research Institute	1U24HL13569101	47,277	-
Cardiovascular Diseases Research	93.837	New England Research Institute	4U10HL06827015	6,866	-
Cardiovascular Diseases Research	93.837	New York University School of Medicine	5R01HL04509527	19,747	-
Cardiovascular Diseases Research	93.837	New York University School of Medicine	5R01HL04509528	3,563	-
Cardiovascular Diseases Research	93.837	Northwestern University	1R01HL13694202	3,679	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Cardiovascular Diseases Research	93.837	Northwestern University	1R01HL13694201	31,456	-
Cardiovascular Diseases Research	93.837	Pennsylvania State University	5U10HL09811507	246,769	-
Cardiovascular Diseases Research	93.837	Rightcare Solutions, Inc.	4R44HL12492303	(139)	-
Cardiovascular Diseases Research	93.837	Sentiar, Inc	1R44HL14089601	17,673	-
Cardiovascular Diseases Research	93.837	St. Louis University	5R01HL12542403	108,168	-
Cardiovascular Diseases Research	93.837	University of Alabama	5U01HL12033803	44,768	-
Cardiovascular Diseases Research	93.837	University of California, Davis	1UG3HL14180001	490,784	-
Cardiovascular Diseases Research	93.837	University of Cincinnati	5U01HL13175502	1,011	-
Cardiovascular Diseases Research	93.837	University of Kentucky	5R01HL09135708	225,668	-
Cardiovascular Diseases Research	93.837	University of Kentucky	7R01HL05567320	181,591	-
Cardiovascular Diseases Research	93.837	University of Michigan	4U01HL09434506	3,625	-
Cardiovascular Diseases Research	93.837	University of North Carolina, Chapel Hill	5U54HL09645813	6,728	-
Cardiovascular Diseases Research	93.837	University of North Carolina, Chapel Hill	5U54HL09645814	35,113	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	1R01HL13490501	50,164	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	5R01HL13490502	33,284	-
Cardiovascular Diseases Research	93.837	University of Rochester	1R34HL13352601	13,622	-
Cardiovascular Diseases Research	93.837	University of South Florida	R01HL073646	21,118	-
Cardiovascular Diseases Research	93.837	Wayne State University	5R01HL10909004	29,283	-
Cardiovascular Diseases Research	93.837	Wayne State University	5R01HL11145905	3,500	-
Lung Diseases Research	93.838			9,758,289	299,971
Lung Diseases Research	93.838	Boston Children's Hospital	4U01HL10768105	(135)	-
Lung Diseases Research	93.838	Brigham & Women's Hospital	5P01HL13282502	86,172	-
Lung Diseases Research	93.838	Case Western Reserve University	5P01HL10187106	956	-
Lung Diseases Research	93.838	Children's Hospital Medical Center	5U01HL13474502	28,075	-
Lung Diseases Research	93.838	Children's Hospital Medical Center	5U01HL13474503	842	-
Lung Diseases Research	93.838	Indiana University	5R01HL11621103	(202)	-
Lung Diseases Research	93.838	Palo Alto Medical Foundation	5R01HL11984503	(864)	-
Lung Diseases Research	93.838	Pennsylvania State University	3U10HL10908606S1	14,478	-
Lung Diseases Research	93.838	Pennsylvania State University	4U10HL10908606	28,438	-
Lung Diseases Research	93.838	Seattle Children's Hospital	1U01HL11462301A1	6,727	-
Lung Diseases Research	93.838	University of Arizona	1U01HL3004501	(109)	-
Lung Diseases Research	93.838	University of Arizona	5U01HL3004502	399,184	-
Lung Diseases Research	93.838	University of Arizona	5U01HL3004503	25,091	-
Lung Diseases Research	93.838	University of Pittsburgh	5R01HL12512803	26,611	-
Lung Diseases Research	93.838	University of Pittsburgh	5U01HL1995203	140,691	-
Lung Diseases Research	93.838	Xemed LLC	5R44HL11239704	6,243	-
Blood Diseases and Resources Research	93.839			8,234,864	782,529
Blood Diseases and Resources Research	93.839	Apt Therapeutics	1R44HL13599301	133,222	-
Blood Diseases and Resources Research	93.839	Kalocyte	5R42HL13596502	102,700	-
Blood Diseases and Resources Research	93.839	Medical University of South Carolina	1R01HL13389601A1	15,431	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840			68,110	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	RASD Rwanda	1U24HL13979001	11,607	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846			13,021,065	557,031
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham & Women's Hospital	4R01AR0555710	316	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham & Women's Hospital	5U01AR06804302	20,201	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Corporation	1R34AR06663101A1	1,658	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Corporation	5R34AR06663102	1,104	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Columbia University Medical Center	2R01AR05783606A1	59,069	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Northwestern University	1U19AR06952601	50,092	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Northwestern University	5UH2AR06768103	(6,582)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Northwestern University	5UH2AR06768104	1,109	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	St. Louis University	5R01AR06482105	14,324	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	St. Louis University	5R01AR06843803	3,398	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Cincinnati	5R21AR06801202	10,451	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Colorado	5R01AR06479304	35,644	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Colorado	5R01AR06479305	16,040	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	1R01AR07087301A1	12,434	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	5R01AR06906202	35,268	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	5R01AR06906203	18,680	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Rochester	4P50AR05404110	26,941	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Rochester	5P50AR05404110	823	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Southern California	1R01AR07221201	44,418	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Texas Houston	1R21AR07287001	12,431	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847			38,248,906	2,269,927
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	U24DK11525501	13,231	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Baylor Research Institute	1R21DK11136902	56,031	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Boston University	5R01DK10150103	60,957	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham & Women's Hospital	5U01DK10430804	17,524	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	California Institute of Technology	2R01DK07893807A1	33,611	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	2U01DK09415707	185,864	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	4U01DK09415706	(1,160)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	DK11481201	1,114	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	1DP3DK10107401	13,317	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	1DP3DK10443801	1,466	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cedars-Sinai Medical Center	2U01DK06241316	43,457	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Mercy Hospital	5U01DK06614315	33,150	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	2U01DK09824606	166,208	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	4U01DK09824605	18,759	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK06123014	164,267	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK06123015	31,869	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Henry M Jackson Foundation For The Advancement of Military Medicine	5R01DK10411501	(1,004)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Henry M Jackson Foundation For The Advancement of Military Medicine	5R01DK10411502	13,898	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Icahn School of Medicine Mount Sinai	2U24DK06242918	31,801	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Icahn School of Medicine Mount Sinai	5U01DK06242917	14,989	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center, Inc.	1UC4DK10110801	60,033	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center, Inc.	2UC4DK10110802	162,881	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	1R01DK10135403	13,645	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK10135404	301,013	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Mcgill University	1R01DK11073701	33,793	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Medical University of South Carolina	5U01DK10483303	64,307	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Nationwide Children's Hospital	4UM1DK10086604	(240)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Nationwide Children's Hospital	5UM1DK10086602	(5,505)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Nationwide Children's Institute	5UM1DK10086605	38,275	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	2R01DK09221404A1	84,501	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	2R01DK09221705	39,366	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Prosthetic Desing, Inc.	PDS141908	4,698	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	REMD Biotherapeutics	4R42DK10830502	210,852	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	St. Louis University	5U01DK08287110	61,488	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	St. Louis University	5R01DK11040602	170,441	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	State University of New York	5R01DK11045602	4,767	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California, San Diego	1UG3DK11493301	85,451	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	2P01DK05678816A1	12,658	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Houston	R21DK11352501A1	20,595	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Illinois	1R01DK11308001A1	20,301	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	3U01DK10832803S1	76	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Michigan	5R01DK10662102	20,714	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Michigan	5R01DK10790402	32,138	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Michigan	5U54DK08391208	10,673	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Michigan	5U54DK08391209	41,961	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	R01DK054481	14,851	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pittsburgh	5U01DK07214610	56,382	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pittsburgh	5U01HD04244415	1,297	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of South Florida	5R01DK10269104	43,159	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Southern California	3U01DK10735002S1	56,889	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Southern California	5U01DK10735003	124,247	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Virginia Commonwealth University	5R01DK09481802	17,711	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Virginia Commonwealth University	5R01DK09481805	15,415	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			36,914,982	2,160,510
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Baylor College of Medicine	1R01NS09365201	17,858	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Bio Rankings, LLC	5R44AG05440502	34,124	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Boston University	1U01NS09333401	10,357	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Boston University	5U01NS09333403	5,168	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Boston University	5U01NS08665904	105,337	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brain Plasticity Institute	5R44NS07178004	3,197	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	California Institute of Technology	1R01NS10221301A1	81,832	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Medical Center	5R01NS09605303	2,972	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Research Institute	7U01NS10768105	16,617	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	5U54TR00145608	9,577	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	5U54TR00145609	125,710	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Jackson Laboratory	1R01NS10263301	130,394	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	T702705	193,998	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	4U01NS08082404	504	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	5U01NS08082405	26,441	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	LA Biomedical Research Institute	1R01NS10081501	41,763	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	LA Biomedical Research Institute	5R01NS10081502	11,448	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1U01NS09025901A1	8,191	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	4U44NS09061602	17,885	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	4K12NS08022305	151,112	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1U01NS07916301	17,496	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS082329	41,340	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS096767	122	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic	1R01NS10321201	2,069	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Michigan State University	R01NS094460	2,399	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mount Sinai School of Medicine	0255-3731-4609	4,775	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	5U01NS0808185	36,041	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Ohio State University	5R01NS09307302	37,614	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Pulse Therapeutics Inc.	4R44NS08908202	24,980	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rutgers University	5U24NS09591402	4	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rutgers University	5U24NS09591403	147,596	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Seattle Children's Hospital	5R01NS09597902	32,760	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Alabama Birmingham	5U01NS09259502	1,634	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, Los Angeles	5R01NS08876603	28,412	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, Los Angeles	5R01NS08876604	33,089	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Diego	1R21NS099766	57,770	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	1U01NS09276401A1	(24)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5U01NS09276402	116,431	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5R01NS07146303	(6)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	1R01NS09429201	94,986	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5U54NS09208903	850	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	4U01NS06283503	16,925	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Michigan	4R01NS07794605	5,115	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh	5R01NS09671403	2,046	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh	5R21HD08780202	584	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh	U01NS107681	620	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Southern California	5R01NS03446720	123,000	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Texas Austin	7R01NS09061703	75,147	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Utah	U01NS095388	536	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Virginia	5U01NS08803404	7,800	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Washington	5R01NS09161803	65,094	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Wayne State University	5R01NS09457002	80,818	-
Allergy and Infectious Diseases Research	93.855			47,475,956	11,426,299
Allergy and Infectious Diseases Research	93.855	Albert Einstein College of Medicine	5R21AI12809002	19	-
Allergy and Infectious Diseases Research	93.855	Baylor College of Medicine	5U01AI095050	(265)	-
Allergy and Infectious Diseases Research	93.855	Boston Children's Hospital	5U01AI12661402	114,204	-
Allergy and Infectious Diseases Research	93.855	Brigham & Women's Hospital	5UM1AI06863612	523,839	-
Allergy and Infectious Diseases Research	93.855	Brigham & Women's Hospital	5UM1AI06863611	207,856	-
Allergy and Infectious Diseases Research	93.855	Case Western Reserve University	5R01AI12520202	(5,501)	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Allergy and Infectious Diseases Research	93.855	Case Western Reserve University	5R01AI2520203	155,407	-
Allergy and Infectious Diseases Research	93.855	Cincinnati Children's Hospital Medical Center	5R01AI11262603	92,914	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Los Angeles	5U54AI08297307	159	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital of Philadelphia	1R01AI13023101A1	188,704	-
Allergy and Infectious Diseases Research	93.855	Drexel University	1U19AI12891001	125,411	-
Allergy and Infectious Diseases Research	93.855	Duke University	5UM1AI10468106	1,795	-
Allergy and Infectious Diseases Research	93.855	Emory University	5R21AI11745902	52,658	-
Allergy and Infectious Diseases Research	93.855	George Washington University	5R01AI12343302	42,193	-
Allergy and Infectious Diseases Research	93.855	George Washington University	5R01AI12343303	33,995	-
Allergy and Infectious Diseases Research	93.855	Georgia State University	5R01AI11465403	91,453	-
Allergy and Infectious Diseases Research	93.855	Georgia State University	5U19AI10944505	675,543	-
Allergy and Infectious Diseases Research	93.855	Georgia State University	7U19AI10944504	92,378	-
Allergy and Infectious Diseases Research	93.855	Icbiome, Inc.	1R43AI13194401A1	4,901	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	1R01AI11191804	86,787	-
Allergy and Infectious Diseases Research	93.855	Michigan State University	1U01AI12661001	8,778	-
Allergy and Infectious Diseases Research	93.855	Michigan State University	5U01AI12661002	105,177	-
Allergy and Infectious Diseases Research	93.855	Microbiotix, Inc	R41AI27009	62,336	-
Allergy and Infectious Diseases Research	93.855	Mount Sinai School of Medicine	5U01AI06359413	6,534	-
Allergy and Infectious Diseases Research	93.855	Mount Sinai School of Medicine	5U01AI06359414	65,131	-
Allergy and Infectious Diseases Research	93.855	Mount Sinai School of Medicine	HHSN272201400008C	296,420	-
Allergy and Infectious Diseases Research	93.855	Ohio State University	R01AI06252011	5,829	-
Allergy and Infectious Diseases Research	93.855	Oregon Health & Science University	5U01AI09577604	(677)	-
Allergy and Infectious Diseases Research	93.855	Oregon Health & Science University	4R01AI09872305	73,537	-
Allergy and Infectious Diseases Research	93.855	Oregon Health & Science University	5R01AI13218602	198,004	-
Allergy and Infectious Diseases Research	93.855	Salk Institute	2R01AI10140005	243,694	-
Allergy and Infectious Diseases Research	93.855	Salk Institute	5R01AI10140006	144,703	-
Allergy and Infectious Diseases Research	93.855	The Benaroya Research Institute	5UM1AI10956503	(1,473)	-
Allergy and Infectious Diseases Research	93.855	The Scripps Research Institute	1R56AI13251501	118,185	-
Allergy and Infectious Diseases Research	93.855	University of Alabama	5U19AI09680004	184,702	-
Allergy and Infectious Diseases Research	93.855	University of Alabama	5U19AI09680005	72,740	-
Allergy and Infectious Diseases Research	93.855	University of Arizona	1R21AI13291001A1	11,946	-
Allergy and Infectious Diseases Research	93.855	University of California, Berkeley	5P01AI10669502	334	-
Allergy and Infectious Diseases Research	93.855	University of California, Berkeley	5P01AI10669503	62,707	-
Allergy and Infectious Diseases Research	93.855	University of California, San Francisco	4U01AI10080705	34,753	-
Allergy and Infectious Diseases Research	93.855	University of California, San Francisco	5U54AI8297309	3,150	-
Allergy and Infectious Diseases Research	93.855	University of Chicago	1R01AI12777401	223,991	-
Allergy and Infectious Diseases Research	93.855	University of Colorado	7R01AI06252012	13,950	-
Allergy and Infectious Diseases Research	93.855	University of Michigan	5R01AI11262604	11,101	-
Allergy and Infectious Diseases Research	93.855	University of North Carolina, Chapel Hill	5U19AI10996504	234,306	-
Allergy and Infectious Diseases Research	93.855	University of North Carolina, Chapel Hill	5U19AI10996505	52,709	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	5R01AI12334805	302,281	-
Allergy and Infectious Diseases Research	93.855	University of South Florida	5R01AI06447809	90,571	-
Allergy and Infectious Diseases Research	93.855	University of Texas Austin	1R21AI12950501	17,671	-
Allergy and Infectious Diseases Research	93.855	University of Texas Health Science Center At San Antonio	5U19AI07041210	138,566	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Allergy and Infectious Diseases Research	93.855	University of Vermont	2R01AI05145411A1	63,719	-
Allergy and Infectious Diseases Research	93.855	University of Washington	5R01AI10400205	252,799	-
Allergy and Infectious Diseases Research	93.855	University of Washington	5U19AI08301909	400,147	-
Allergy and Infectious Diseases Research	93.855	University of Washington	5U19AI08301910	68,190	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	1R01AI13251901A1	1,733	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5UM1AI11427103	62,102	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5UM1AI11427104	582,483	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	4U19AI10677204	6,735	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5U19AI10677205	447,833	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	5U01AI10433606	36,400	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	501AI12782802	202,504	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5R01AI11481604	137,810	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5R01AI11481605	103,956	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1AI06943912	147,930	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1AI06943913	202,038	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1AI06861912	694,797	-
Allergy and Infectious Diseases Research	93.855	Vaxnewmo	1R41AI13174201	72,503	-
Allergy and Infectious Diseases Research	93.855	Vaxnewmo	1R41AI13623301	17,593	-
Microbiology and Infectious Diseases Research	93.856			208,116	94,459
Biomedical Research and Research Training	93.859			23,115,651	895,512
Biomedical Research and Research Training	93.859	California Institute of Technology	R01GM084211	90,148	-
Biomedical Research and Research Training	93.859	Nationwide Children's Hospital	5R01GM094230305	488	-
Biomedical Research and Research Training	93.859	North Carolina State University	5R01GM11323905	3,624	-
Biomedical Research and Research Training	93.859	Protein Metrics	1R41GM12113301A1	21,149	-
Biomedical Research and Research Training	93.859	Radiologics	1R44GM12543801	5,993	-
Biomedical Research and Research Training	93.859	Stanford University	1R01GM10607804	115,524	-
Biomedical Research and Research Training	93.859	University of Colorado, Denver	1R01GM12374601	32,960	-
Biomedical Research and Research Training	93.859	University of Michigan	5R01GM09583206	25,690	-
Biomedical Research and Research Training	93.859	University of Michigan	2U54GM10329706	149,798	-
Biomedical Research and Research Training	93.859	University of Michigan	4P50GM10329705	10,894	-
Biomedical Research and Research Training	93.859	University of Pittsburgh	5R01GM10038705	19,743	-
Biomedical Research and Research Training	93.859	University of Texas, Austin	5R01GM11423704	202,738	-
Child Health and Human Development Extramural Research	93.864			126,939	-
Child Health and Human Development Extramural Research	93.865			15,647,844	4,696,567
Child Health and Human Development Extramural Research	93.865	Cincinnati Children's Hospital Medical Center	2K12HD00085003	87,551	-
Child Health and Human Development Extramural Research	93.865	Cincinnati Children's Hospital Medical Center	5R01HD08601103	6,799	-
Child Health and Human Development Extramural Research	93.865	Cincinnati Children's Hospital Medical Center	1R01HD08601101A1	(763)	-
Child Health and Human Development Extramural Research	93.865	Cincinnati Children's Hospital Medical Center	5K12HD00085032	174	-
Child Health and Human Development Extramural Research	93.865	Cincinnati Children's Hospital Medical Center	5R01HD08601102	75,933	-
Child Health and Human Development Extramural Research	93.865	Columbia University	1R01HD09100301	13,912	-
Child Health and Human Development Extramural Research	93.865	Inquisit Health, Inc.	5R44HD08183003	4,971	-
Child Health and Human Development Extramural Research	93.865	Nemours Children's Clinic	5R01HD07846305	140,736	-
Child Health and Human Development Extramural Research	93.865	Nemours Children's Clinic	5R01HD07846303	38,890	-
Child Health and Human Development Extramural Research	93.865	Oklahoma State University	5R01HD07457907	890	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Child Health and Human Development Extramural Research	93.865	Oklahoma State University	7R01HD07457906	3,902	-
Child Health and Human Development Extramural Research	93.865	Pennsylvania State University	5DP1HD08607103	1,791	-
Child Health and Human Development Extramural Research	93.865	Pennsylvania State University	5DP1HD08607104	1,066	-
Child Health and Human Development Extramural Research	93.865	Preemie Pacer LLC	R43HD032210WU	33,803	-
Child Health and Human Development Extramural Research	93.865	Research Foundation For The State University of New York	5R01HD08029203	37,941	-
Child Health and Human Development Extramural Research	93.865	Seattle Children's Hospital	5R01HD07336205	727	-
Child Health and Human Development Extramural Research	93.865	University of California, Davis	U01HD062417	(68)	-
Child Health and Human Development Extramural Research	93.865	University of California, Los Angeles	5R01HD09247102	7,460	-
Child Health and Human Development Extramural Research	93.865	University of California, San Francisco	1R01HD09241901	132,712	-
Child Health and Human Development Extramural Research	93.865	University of Michigan	1R01HD08523302	(18,356)	-
Child Health and Human Development Extramural Research	93.865	University of Michigan	7R01HD08523303	49,157	-
Child Health and Human Development Extramural Research	93.865	University of North Carolina, Chapel Hill	2R01HD05574111	290,144	-
Child Health and Human Development Extramural Research	93.865	University of North Carolina, Chapel Hill	4R01HD05574110	56,534	-
Child Health and Human Development Extramural Research	93.865	University of Southern California	5R01HD08134603	46,328	-
Child Health and Human Development Extramural Research	93.865	University of Texas Southwestern Medical Center	1P01HD08438701A1	333,311	-
Child Health and Human Development Extramural Research	93.865	University of Wisconsin, Madison	5R01HD08300102	126,540	-
Child Health and Human Development Extramural Research	93.865	Vanderbilt University	5U01HD07673305	6,577	-
Child Health and Human Development Extramural Research	93.865	Yale University	5U01HD05592510	258	-
Child Health and Human Development Extramural Research	93.865	Yale University	1R21HD08913101A1	5,658	-
Aging Research	93.866			44,087,843	6,610,507
Aging Research	93.866	Beckman Research Institute of The City of Hope	5R01AG03703705	(25,074)	-
Aging Research	93.866	Cognition Therapeutics, Inc.	1RF1AG05778001	273,743	-
Aging Research	93.866	Columbia University	1U24AG05627001	68,534	-
Aging Research	93.866	Columbia University	5R01AG04179705	6,513	-
Aging Research	93.866	Duke University	7R24AG05435503	32,300	-
Aging Research	93.866	Hebrew Rehabilitation Center	5R24AG05425902	10,754	-
Aging Research	93.866	Icahn School of Medicine Mount Sinai	5U01AG05241102	220,665	-
Aging Research	93.866	Mayo Clinic	5U01AG04539003	(9,797)	-
Aging Research	93.866	Mayo Clinic	5U01AG04539004	137,475	-
Aging Research	93.866	Neural Stem Cell Institute	1R01AG05629301	64,255	-
Aging Research	93.866	Northern California Institute For Research & Education	2U19AG02490411	42,340	-
Aging Research	93.866	Northern California Institute For Research & Education	5U19AG02490412	136,257	-
Aging Research	93.866	Northwestern University	5R01AG04741603	16,506	-
Aging Research	93.866	St. Louis University	5K01AG04907504	6,232	-
Aging Research	93.866	University of California, San Diego	5U01AG01048326	60,182	-
Aging Research	93.866	University of California, San Francisco	2R01AG03879106A1	6,070	-
Aging Research	93.866	University of California, San Francisco	5R01AG04561105	15,268	-
Aging Research	93.866	University of Nebraska Medical Center	5R01AG03712005	2,678	-
Aging Research	93.866	University of Pennsylvania	1R01AG05443501A1	195,272	-
Aging Research	93.866	University of Pennsylvania	5R01AG04150205	64,009	-
Aging Research	93.866	University of Pittsburgh	5U01AG05140602	(37,052)	-
Aging Research	93.866	University of Pittsburgh	5U01AG05140603	121,589	-
Aging Research	93.866	University of Southern California	5U01AG02490410	60,431	-
Aging Research	93.866	University of Southern California	5U19AG01048325	13,641	-

The accompanying notes are an integral part of this schedule.



# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Aging Research	93.866	University of Southern California	5P01AG05235002	93,256	-
Aging Research	93.866	University of Southern California	5P01AG05235003	73,453	-
Aging Research	93.866	University of Southern California	2U19AG02490412	63,728	-
Aging Research	93.866	University of Southern California	RF1AG041845	(1,652)	-
Aging Research	93.866	University of Texas, Austin	1R21AG052060	83,324	-
Aging Research	93.866	University of Texas Southwestern Medical Center	5R01AG04974902	368,147	-
Aging Research	93.866	University of Texas Southwestern Medical Center	5R01AG04867804	177,218	-
Aging Research	93.866	University of Virginia	5R21AG05206202	7,062	-
Aging Research	93.866	University of Washington	5U01AG01697619	56,904	-
Vision Research	93.867			12,478,687	1,936,862
Vision Research	93.867	Boston University	5R21EY02759002	102,289	-
Vision Research	93.867	Case Western Reserve University	1R24EY02728301	108,406	-
Vision Research	93.867	Case Western Reserve University	5U01EY02545103	46,681	-
Vision Research	93.867	Duke University	5R01EY02500903	72,092	-
Vision Research	93.867	Johns Hopkins University	5R01EY01701510	63,901	-
Vision Research	93.867	Johns Hopkins University	5U10EY02452702	2,911	-
Vision Research	93.867	New York University School of Medicine	1U10EY02686901	4,863	-
Vision Research	93.867	University of Illinois	R21EY02761202	90,898	-
Vision Research	93.867	University of Michigan	5R01Y02664102	8,334	-
Vision Research	93.867	University of Texas M.D Anderson Cancer Center	5R01EY01958716	(88)	-
Vision Research	93.867	Viewpoint Therapeutics, Inc.	1R43EY02647401	20,451	-
Medical Library Assistance	93.879			481,566	102,556
Medical Library Assistance	93.879	California Institute of Technology	1U01LM012672A01	12,650	-
Medical Library Assistance	93.879	University of Arkansas	1R01LM01248201	23,638	-
Medical Library Assistance	93.879	University of Arkansas	5R01LM01248202	122,416	-
Global Health Research and Research Training	93.989	Regional Alliance for Sustainable Development (RASD) Rwanda	5D43TW01033503	74,265	-
Global Health Research and Research Training	93.989	Vanderbilt University Medical Center	5UM1AI06861911	(104,367)	-
Fogarty International Center (FIC)	93	Implementation Science Network	ISN AWARD	23,643	-
National Cancer Institute (NCI)	93	Massachusetts General Hospital	218211	(7,501)	-
National Cancer Institute (NCI)	93	Massachusetts General Hospital	220778	59,756	-
National Cancer Institute (NCI)	93	Massachusetts General Hospital	2U19CA02123939	375,951	-
National Cancer Institute (NCI)	93	American College of Radiology	ACRIN6685	71	-
National Cancer Institute (NCI)	93	National Childhood Cancer Foundation	TMP2496	(789)	-
National Cancer Institute (NCI)	93	NRG Oncology Foundation	LPMO011	96,416	37,242
National Cancer Institute (NCI)	93	Queen's University at Kingston	TMP2763	(6,144)	-
National Cancer Institute (NCI)	93	Westat	HHSN2612016000071	19,390	-
National Heart, Lung and Blood Institute (NHLBI)	93			11,566	-
National Heart, Lung and Blood Institute (NHLBI)	93	Ocean Nanotech, LLC	HHSN268201400042C	217,430	-
National Heart, Lung and Blood Institute (NHLBI)	93	Radiological Society of North America	HHSN26820120078C	165,372	-
National Heart, Lung and Blood Institute (NHLBI)	93	University of Michigan	HHSN268201100026C	7,675	-
National Institute of Allergy and Infectious Diseases (NIAID)	93			3,076,619	797,254
National Institute of Allergy and Infectious Diseases (NIAID)	93	Emory University	HHSN272201200031C	1,347	-
National Institute of Allergy and Infectious Diseases (NIAID)	93	Integral Molecular	HHSN272201400058C	88,656	-

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
National Institute of Allergy and Infectious Diseases (NIAID)	93	Northwestern University	HHSN272201200026C	67,163	-
National Institute of Allergy and Infectious Diseases (NIAID)	93	Northwestern University	HHSN272201700060C	441,655	-
National Institute of Allergy and Infectious Diseases (NIAID)	93	Rutgers University	HHSN271201400020C	241,891	-
National Institute of Allergy and Infectious Diseases (NIAID)	93	St. Jude Children's Research Institute	HHSN272201400006C	14,086	-
National Institute of Allergy and Infectious Diseases (NIAID)	93	University of Alabama, Birmingham	HHSN272201100036C	2,969	-
National Institute of Allergy and Infectious Diseases (NIAID)	93	University of Alabama, Birmingham	HHSN272201100035C	12,561	-
National Institute of Allergy and Infectious Diseases (NIAID)	93	University of Alabama, Birmingham	HHSN272201100037C	7,687	-
National Institute of Allergy and Infectious Diseases (NIAID)	93	University of Rochester	HHSN272201200005C	55,414	-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	93	George Washington University	TRIALNET	17,706	-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	93	Children's Mercy Hospital	5U01DK06614302	9,435	-
National Institute of Health Clinical Research Center	93			17,289	-
National Institutes of Health (NIH)	93	Albert Einstein College of Medicine		41,888	-
National Institutes of Health (NIH)	93	American College of Radiology	TMP2135	15,791	-
National Institutes of Health (NIH)	93	NIH/American College of Surgeons	Z1071	130	-
National Institutes of Health (NIH)	93	Case Western Reserve University	CTN0801	(314)	-
National Institutes of Health (NIH)	93	Etiometry	2R44HL11734005	2,950	-
National Institutes of Health (NIH)	93	ICF Macro Inc.	HHSN26120140002B	58,499	-
National Institutes of Health (NIH)	93	Mathmatica	HHSP2332015000351/HHSP233	71,646	-
National Institutes of Health (NIH)	93	NSABP Foundation	STAR	66,657	-
National Institutes of Health (NIH)	93	University of Colorado, Denver	CER150327915	(22,233)	-
National Institutes of Health (NIH)	93	University of Missouri	CLARK16Po	23,676	-
<b>Substance Abuse and Mental Health Services Administration</b>					
Projects of Regional and National Significance	93.243			177,775	-
Substance Abuse and Mental Health Services Administration	93	St. Louis County	SAMHSA	8,969	-
<b>TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES</b>				<b>457,377,945</b>	<b>59,794,666</b>
<b>NATIONAL AERONAUTICS AND SPACE ADMINISTRATION</b>					
<b>National Aeronautics and Space Administration</b>					
Science	43.001			5,341,499	43,611
Science	43.001	Bay Area Environmental Research	NNX17AC02G	54,860	-
Science	43.001	Brown University	NNX16AG49G	46,363	-
Science	43.001	California Institute of Technology	NNX13AH66G	64,193	-
Science	43.001	California Institute of Technology	NNX15AH53G	45,566	-
Science	43.001	California Institute of Technology	80NSSC18K0223	38,456	-
Science	43.001	Cornell University	JPL1536058	244,179	-
Science	43.001	Johns Hopkins University	80NSSC17K0418	7,254	-
Science	43.001	Smithsonian Astrophysical Observatory	NASA03060	55,980	-
Science	43.001	University of New Mexico	NNX17AE25G	26,791	-
Science	43.001	University of Washington	NNA13AA39A	28,722	-
Space Operations	43.007			293,646	-
Education	43.008	Missouri University of Science and Technology	NNX14AN17A	149,096	-
Education	43.008	Missouri University of Science and Technology	NNX15AK03H	38,269	-
Space Technology	43.012			209,073	-
NASA	43	Arizona State University	NNG07EK00C	118,554	-
Jet Propulsion Laboratory	43	Jet Propulsion Laboratory	1575459	16,666	-
Jet Propulsion Laboratory	43	Jet Propulsion Laboratory	NM0710630	44,107	-
Jet Propulsion Laboratory	43	Jet Propulsion Laboratory	NM0710805	108,842	-
Jet Propulsion Laboratory	43	Jet Propulsion Laboratory	NNN12A01C	63,805	-
Jet Propulsion Laboratory	43	Jet Propulsion Laboratory	NNN12AA01C	196,189	-
NASA	43	Johns Hopkins University	JPL1277793	93,746	-
NASA	43	Southwest Research Institute	H99063CT	15,140	-
NASA	43	Southwest Research Institute	NASW02008	18,837	-
NASA	43	University of Texas Austin	NNM16AA26C	20,828	-
<b>TOTAL NATIONAL AERONAUTICS AND SPACE ADMINISTRATION</b>				<b>7,340,659</b>	<b>43,611</b>

The accompanying notes are an integral part of this schedule.

# Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
<b>NATIONAL SCIENCE FOUNDATION</b>					
<b>National Science Foundation</b>					
Engineering Grants	47.041			3,017,260	365,270
Engineering Grants	47.041	Arch Innotek, LLC	1722313	64,810	-
Engineering Grants	47.041	Rensselaer Polytechnic Institute	EFRI1433311	98,993	-
Engineering Grants	47.041	University of Illinois	1512043	59,060	-
Engineering Grants	47.041	University of Illinois	1740737	56,091	-
Engineering Grants	47.041	University of Pennsylvania	CMMI1548571	677,624	-
Engineering Grants	47.041	University of Texas at Austin	1710922	56,546	-
Engineering Grants	47.041	Yale University	1542815	61,369	-
Mathematic and Physical Sciences	47.049			3,202,089	26,663
Mathematic and Physical Sciences	47.049	Oregon State University	1606982	103,591	-
Mathematic and Physical Sciences	47.049	Oregon State University	S1412AA CHE112637	(2,644)	-
Geosciences	47.050			1,028,387	-
Geosciences	47.050	Cornell University	1654568	163,956	-
Computer and Information Science and Engineering	47.070			2,634,056	29,304
Computer and Information Science and Engineering	47.070	Virginia Polytech Institute	ACL4547580	20,000	-
Computer and Information Science and Engineering	47.070	University of California, Berkely	NSF1640899	125,760	-
Biological Sciences	47.074			4,691,977	326,294
Biological Sciences	47.074	Michigan State University	1644965	8,508	-
Biological Sciences	47.074	Michigan State University	CNS1405273	156,152	-
Biological Sciences	47.074	Michigan State University	IOS1455405 NSF	1,601	-
Biological Sciences	47.074	University of Wisconsin, Madison	IOS-1339325	1,612	-
Social, Behavioral, and Economic Sciences	47.075			883,834	11,982
Social, Behavioral, and Economic Sciences	47.075	Colorado State University	SMA1519987	104,370	-
Social, Behavioral, and Economic Sciences	47.075	Georgia State University	1740201	19,536	-
Education and Human Resources	47.076			1,693,284	-
Education and Human Resources	47.076	Business-Higher Education Forum	DUE1331063	84,958	-
Education and Human Resources	47.076	Harris-Stowe State University	1619639	134,760	-
Education and Human Resources	47.076	Indiana University	DUE1534014	112,200	-
Education and Human Resources	47.076	University of Wisconsin	1726625	14,546	-
Office of International Science and Engineering	47.079	Arkansas Science and Technology Authority	IIA-1430427(NSF)	4,541	-
Office of International Science and Engineering	47.079	University of Missouri	IIA1430428NSF	127,091	-
Office of Integrative Activities	47.083	University of Missouri	OIA-1355406	252,737	-
<b>TOTAL NATIONAL SCIENCE FOUNDATION</b>				<b>19,658,655</b>	<b>759,512</b>
<b>RESEARCH &amp; DEVELOPMENT PROGRAMS FROM OTHER FEDERAL AGENCIES</b>					
<b>AGENCY FOR INTERNATIONAL DEVELOPMENT</b>					
<b>Agency for International Development</b>					
Agency for International Development	98	Drugs for Neglected Diseases	AIDOAG1400010	151,226	-
Agency for International Development	98	International AIDS Vaccine Initiative	AID0AAA1600032	253	-
Agency for International Development	98	Michigan State University	EDHA00070000500	580,826	122,382
Agency for International Development	98	National Academy of Sciences	ESPA00050000100	91,115	-
Agency for International Development	98	Task Force for Global Health	AIDOAG1400008	65,673	-
Agency for International Development	98	Tufts University	AID0AAC1600020	582,034	112,092
<b>DEPARTMENT OF AGRICULTURE</b>					
<b>Agricultural Research Service</b>					
Agricultural Research - Basic and Applied Research	10.001			39,624	-

The accompanying notes are an integral part of this schedule.

# Washington University

## Schedule of Expenditures of Federal Awards

### For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
<b>National Institute of Food and Agriculture</b>					
Biotechnology Risk Assessment Research	10.219			70,731	-
Agriculture and Food Research Initiative (AFRI)	10.310			146,661	58,610
Agriculture and Food Research Initiative (AFRI)	10.310	University of Rhode Island	20158701622942	12,751	-
<b>DEPARTMENT OF COMMERCE</b>					
<b>National Institute of Standards and Technology</b>					
Science, Technology, Business and/or Education Outreach	11.620			5,500	-
<b>DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT</b>					
<b>Department of Housing and Urban Development</b>					
Office of Healthy Homes and Lead Hazard Control	14			122,353	-
Healthy Homes Technical Studies Grants	14.906			75,797	-
<b>DEPARTMENT OF THE INTERIOR</b>					
<b>U.S. Geological Survey</b>					
Research & Data Collection	15.808			18,831	-
<b>DEPARTMENT OF JUSTICE</b>					
<b>Violence Against Women Office</b>					
OVW Research and Evaluation Program	16.026			87,237	-
Department of Justice	16.123	City of St. Louis	18-51	6,463	-
Department of Justice	16.830	Annie Malone Children & Family Services	2016GJFXK006	20,082	-
<b>DEPARTMENT OF TRANSPORTATION</b>					
<b>Federal Highway Administration</b>					
Police Traffic Services	20.600	Missouri Dept of Transportation	18DL02002	94,032	-
<b>DEPARTMENT OF THE TREASURY</b>					
<b>DEPARTMENT OF VETERANS AFFAIRS</b>					
Department of Veterans Affairs	64			6,487	-
<b>ENVIRONMENTAL PROTECTION AGENCY</b>					
Office of Research and Development					
Science To Achieve Results (STAR) Research Program	66.509	Missouri University of Science and Technology	83575101	41,712	-
<b>NATIONAL ENDOWMENT FOR THE HUMANITIES</b>					
Promotion of the Humanities - Fellowships and Stipends	45.160			25,200	-
<b>NATIONAL FILM PRESERVATION FOUNDATION</b>					
National Film Preservation Foundation	89			3,645	-
<b>Total R&amp;D Programs from Other Federal Agencies</b>				<u>2,248,231</u>	<u>293,084</u>
<b>Total Research &amp; Development Cluster</b>				<u>512,451,317</u>	<u>55,733,158</u>
<b>Other Sponsored Programs</b>					
<b>DEPARTMENT OF DEFENSE</b>					
<b>U.S. Army Medical Command</b>					
Military Medical Research and Development	12.420	Boston Children's Hospital	W81XWH1710532	16,160	-
Military Medical Research and Development	12.420	Neumedices, Inc.	2015-SWI-004	85,334	-
Military Medical Research and Development	12.420	Sarcoma Alliance	W81XWH1310072	4,346	-
Military Medical Research and Development	12.420	University of Alabama, Birmingham	W81XWH1210155	5,061	-
Military Medical Research and Development	12.420	University of Alabama, Birmingham	W81XWH1720037	1,336	-

The accompanying notes are an integral part of this schedule.

# Washington University

## Schedule of Expenditures of Federal Awards

### For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Military Medical Research and Development	12.420	University of Colorado	W81XWH1510504	19,637	-
TOTAL MILITARY MEDICAL RESEARCH AND DEVELOPMENT				131,874	-
<b>U.S. Army</b>					
U.S. Army	12	Johns Hopkins University	W81XWH1020134	336	-
				132,210	-
<b>DEPARTMENT OF HEALTH AND HUMAN SERVICES</b>					
<b>Administration for Children and Families</b>					
Healthy Marriage Promotion and Responsible Fatherhood Grants	93.086	Fathers Support Center St. Louis	HHS2015ACFOFAFK0993	302,763	-
<b>Agency for Healthcare Research and Quality</b>					
Research on Healthcare Costs, Quality and Outcomes	93.226			28,997	-
<b>Centers for Disease Control</b>					
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of Texas Health Science Center	5NU27DD0011550300	9,702	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of Texas Health Science Center	5NU27DD0011550200	6,651	-
TOTAL BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH				16,353	-
CBA to Strengthen Public Health Infrastructure and Performance	93.424	National Association for Chronic Disease	5NU38OT00022505	60,000	-
Centers for Disease Control and Prevention	93.757	State of Missouri	5NU58DP00481705	52,363	-
HIV Prevention Activities_Non-Governmental Organization Based	93.939	University of Missouri, Kansas City	5U65PS00448105	6,391	-
HIV Prevention Activities_Non-Governmental Organization Based	93.939	University of Missouri, Kansas City	5U65PS00448104	16,104	-
TOTAL HIV PREVENTION ACTIVITIES_NON-GOVERNMENTAL ORGANIZATION BASED				22,495	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	HRSA1166	97,807	-
Centers for Disease Control and Prevention	93			490,019	-
<b>Department of Health and Human Services</b>					
Department of Health and Human Services	93	Health Research Inc.	HRSA15-0696-05	(152)	-
Department of Health and Human Services	93	Healthcore, Inc.	200201142070005	75,256	42,514
Department of Health and Human Services	93	St. Louis Effort for AIDS	PDS156548	227,887	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				302,991	42,514
Food and Drug Administration_Research	93.103	Johns Hopkins University	5R01FD00481904	196	-
<b>Health Resources and Services Administration</b>					
Trans-NIH Research Support	93.110	University of Texas Health Science Center At San Antonio	2H30MC2405106	21,892	-
Trans-NIH Research Support	93.110	University of Texas Health Science Center At San Antonio	5H30MC240510700	171	-
TOTAL TRANS-NIH RESEARCH SUPPORT				22,063	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	6U03MC226840601	17,275	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	6U03MC226840701	62,263	-
TOTAL EMERGENCY MEDICAL SERVICES FOR CHILDREN				79,538	-
Grants to Increase Organ Donations	93.134	University of Arizona	6U13HS305860101	2,579	-
Grants to Increase Organ Donations	93.134	University of Arizona	5U13HS305860200	8,896	-
TOTAL GRANTS TO INCREASE ORGAN DONATIONS				11,475	-
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153			1,340,137	98,540
Sickle Cell Treatment Demonstration Program	93.365			618,070	346,906
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	HRSA1166CTR7113549	139,023	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	USDHHS - RYAN WHITE	1,012,746	-
TOTAL HIV EMERGENCY RELIEF PROJECT GRANTS				1,151,769	-
HIV Care Formula Grants	93.917	St. Clair County	RYAN WHITE HIV/AIDS	66,728	67,080
HIV Care Formula Grants	93.917	State of Missouri	DH1706A00003	382,809	-

The accompanying notes are an integral part of this schedule.

# Washington University

## Schedule of Expenditures of Federal Awards

### For the Year Ended June 30, 2018

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
HIV Care Formula Grants	93.917	State of Missouri	RFA 1706	108,204	13,150
TOTAL HIV CARE FORMULA GRANTS				557,741	80,230
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918			625,464	26,674
Special Projects of National Significance	93.928			339,143	-
<b>Office of Minority Health</b>					
Community Programs to Improve Minority Health	93.137	St. Louis Integrated Health	ICPIMP1611360200	55,880	-
Community Programs to Improve Minority Health	93.137	St. Louis Integrated Health	ICPIMP1611360100	703	-
TOTAL COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH				56,583	-
<b>Office of Population Affairs</b>					
Family Planning Services	93.217	Missouri Family Health Council	DHHS TITLE X	186,287	-
<b>Office of the Secretary of Health and Human Services</b>					
Research on Research Integrity	93.085			140,488	-
<b>Substance Abuse and Mental Health Services Administration</b>					
Substance Abuse and Mental Health Services_ Projects of Regional and National Significance	93.243			412,939	-
				6,915,681	594,864
<b>OTHER FEDERAL PROGRAMS</b>					
<b>DEPARTMENT OF JUSTICE</b>					
<b>Office of Juvenile Justice and Delinquency Prevention</b>					
Children of Incarcerated Parents	16.831	Fathers Support Center	2014IGBX0005	(5,180)	-
Department of Justice	16.123	United Way of Greater St. Louis	2016MUMUK012	52,848	-
<b>DEPARTMENT OF THE TREASURY</b>					
<b>Internal Revenue Service</b>					
Low Income Taxpayer Clinics	21.008			97,552	-
<b>INSTITUTE OF MUSEUM AND LIBRARY SERVICE</b>					
Museums for America	45.301			15,694	-
National Leadership Grants	45.312			44,304	-
<b>NATIONAL ARCHIVES AND RECORDS ADMINISTRATION</b>					
<b>National Archives and Records Administration</b>					
National Historical Publications and Records Grants	89.003			22,918	-
<b>NATIONAL ENDOWMENT FOR THE HUMANITIES</b>					
Promotion of the Humanities - Challenge Grants	45.130			4,213	-
Promotion of the Humanities Fellowships and Stipends	45.160			71,400	-
<b>Total Other Sponsored Programs from Other Federal Agencies</b>				303,750	-
<b>Total Other Sponsored Programs</b>				7,351,640	594,864
<b>Student Financial Assistance Cluster</b>					
<b>DEPARTMENT OF EDUCATION</b>					
Federal Supplemental Educational Opportunity Grant	84.007			1,213,814	-
Federal Work-Study Program	84.033			1,130,721	-
Federal Pell Grant Program	84.063			4,113,615	-
<b>Federal Direct Student Loans</b>					
Outstanding Loans as of July 1, 2017	84.268			-	-
New Loans Issued during 2018	84.268			85,489,972	-
Administrative Cost Allowance	84.268			-	-
<b>Federal Perkins Loans</b>					
Outstanding Loans as of July 1, 2017	84.038			39,564,017	-
New Loans Issued during 2018	84.038			542,902	-
Administrative Cost Allowance	84.038			65,000	-
<b>DEPARTMENT OF HEALTH AND HUMAN SERVICES</b>					
<b>Health Professions Student Loans including Primary Care Loans/Loans for Disadvantaged Students</b>					
Outstanding Loans as of July 1, 2017	93.242			197,738	-
New Loans Issued during 2018	93.242			-	-
Administrative Cost Allowance	93.242			-	-
<b>Total Student Financial Assistance Cluster</b>				132,317,779	-
<b>TRIO Cluster</b>					
<b>DEPARTMENT OF EDUCATION</b>					
TRIO - Student Support Services	84.042			351,400	-
<b>Total Federal Award Expenditures</b>				\$ 652,472,136	\$ 56,328,022

The accompanying notes are an integral part of this schedule.

# Washington University

## Notes to Schedule of Expenditures of Federal Awards

### For the Year Ended June 30, 2018

---

#### 1. Summary of Significant Accounting Policies

##### Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) summarizes the expenditures of Washington University (the “university”) under programs of the Federal Government for the year ended June 30, 2018. Expenditures of direct awards to the university are reported in total by program. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulation Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the basic financial statements. The university includes the amounts in the Schedule in the unrestricted net assets of the university’s Consolidated Statement of Activities for the year ended June 30, 2018.

The Schedule is prepared on the accrual basis of accounting. Expenditures are recognized following the cost accounting principles contained in the Uniform Guidance wherein certain types of expenditures are not allowable or are limited to reimbursement. Moreover, expenditures include a portion of costs associated with general university activities which are allocated to awards under negotiated formulas commonly referred to as facilities and administrative cost rates.

##### Federal Awards

For purposes of the Schedule, federal awards include all grants, contracts and similar agreements entered into directly by the university with agencies and departments of the Federal Government and all awards received as a subrecipient from nonfederal organizations pursuant to federal grants, contracts and similar agreements.

#### 2. Facilities and Administrative Costs

The university recovers facilities and administrative costs under federal financial assistance programs using predetermined rates ranging from 25.5% to 54.5%. The university does not use the 10% de minimis cost rate but instead has negotiated the rates above with the Department of Health and Human Services through June 30, 2021.

#### 3. Federal Student Loan Programs

The following schedule includes the SFA loan balances outstanding as of June 30, 2018:

Student Financial Aid	Federal CFDA Number	Outstanding Balances
<b>U.S. Department of Education</b>		
Federal Perkins Loan Program	84.038	\$ 32,688,558
<b>U.S. Department of Health and Human Services</b>		
Health Profession Student Loans, Primary Care Loans	93.342	\$ 158,174

The university had an Administrative Cost Allowance (ACA) of \$65,000 for fiscal year 2018.

## **Reports on Compliance and on Internal Controls**





## **Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards***

To the Board of Trustees of Washington University

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Washington University (the “university”), which comprise the consolidated statement of financial position as of June 30, 2018, and the related consolidated changes in its net assets and its cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated September 25, 2018.

### **Internal Control Over Financial Reporting**

In planning and performing our audit of the financial statements, we considered the university’s internal control over financial reporting (“internal control”) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the university’s internal control. Accordingly, we do not express an opinion on the effectiveness of the university’s internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

### **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the university’s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



**Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Parsons Brinckerhoff LLP

St. Louis, Missouri  
September 25, 2018



**Report of Independent Auditors on Compliance with Requirements  
That Could Have a Direct and Material Effect on Each Major Program and on Internal  
Control Over Compliance in Accordance with the Uniform Guidance**

To the Board of Trustees of Washington University

**Report on Compliance for Each Major Federal Program**

We have audited Washington University's (the "university") compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the university's major federal programs for the year ended June 30, 2018. The university's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

***Management's Responsibility***

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

***Auditors' Responsibility***

Our responsibility is to express an opinion on compliance for each of the university's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the university's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the university's compliance.

***Opinion on Each Major Federal Program***

In our opinion, the university complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2018.



## Report on Internal Control Over Compliance

Management of the university is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the university's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the university's internal control over compliance.

*A deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

*PricewaterhouseCoopers LLP*

St. Louis, Missouri  
February 19, 2019

**Schedule of Independent Auditors'  
Findings and Questioned Cost**

# Washington University

EIN# 43-0653611

## Schedule of Independent Auditors' Findings and Questioned Costs Year Ended June 30, 2018

---

### Part I - Summary of Auditors' Results

#### Financial Statements

Type of auditors' report issued: Unmodified

Internal control over financial reporting: Material weakness (es) identified?  Yes  No

Significant deficiency (ies) identified not considered to be material weaknesses?  Yes  None reported

Noncompliance material to financial statements noted?  Yes  No

#### Federal Awards

Type of auditor's report issued on compliance for major programs: Unmodified

Internal control over major programs:

Material weakness (es) identified?  Yes  No

Significant deficiency (ies) identified not considered to be material weaknesses?  Yes  None reported

Any audit findings disclosed that are required to be reported in accordance with Uniform Guidance Section 200.516(a)?  Yes  No

#### Identification of Major Programs:

CFDA Number(s)

Various

Various

Dollar threshold used to distinguish between Type A and Type B programs:

Auditee qualified as low-risk auditee?

Name of Federal Program or Cluster

Student Financial Aid Cluster

Research and Development and Research Training Cluster

\$3,000,000

Yes  No

# Washington University

EIN# 43-0653611

## Schedule of Independent Auditors' Findings and Questioned Costs Year Ended June 30, 2018

---

### **Part II – Financial Statement Findings**

There are no financial statement findings to report.

### **Part III – Federal Award Findings and Questioned Costs**

There are no federal award findings and questioned costs to report.

## **Summary of Status of Prior Audit Findings**



**Washington University**  
**Summary of Status of Prior Audit Findings**  
**Year Ended June 30, 2018**

---

There were no federal award findings and questioned costs in the prior year.